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ABSTRACT 
 
A prospective study involving 30 patients, diagnosed to have intractable 
upper abdomen pain due to malignancies/ pathologies of inoperable status at 
BARNARD INSTITUTE OF RADIOLOGY, MADRAS MEDICAL COLLEGE & 
RAJIV GANDHI GOVT GENERAL HOSPITAL, CHENNAI by Dr. H. 
Iyengaran, III year M.D.R.D. resident, as the principal investigator under the 
guidance of  Professor S. Kalpana, M.D., D.M.R.D,. These patients were referred 
from the Institute of Anesthesiology and Critical care and from Department of 
Gastroenterology.  
AIMS AND OBJECTIVES: 
• To perform CT guided neurolysis of the CELIAC PLEXUS, through anterior 
approach in patients with intractable upper abdominal pain due to 
intraabdominal malignancies/pathologies of inoperable status. 
• To assess treatment success by evaluating pain relief using Visual Analog 
Scale (VAS) before and after the procedure. 
• To assess minor/major complications associated with the procedure.  
 
The procedure was done through anterior approach with Absolute alcohol as 
the neurolytic agent. Pain assessment was done using Visual Analog scale. 
 
INDICATIONS: 
• Patients with persistent and intractable upper abdominal pain due to 
malignancies / Chronic Pancreatitis of inoperable status 
• Patients with severe nausea and hyperemesis due to Pancreatic cancer  
• In visceral neuropathy in patients with diabetes, Inflammatory bowel disease 
(Crohn’s disease) and sclerosing cholangitis of AIDS. 
 
CONTRAINDICATIONS: 
• Coagulopathies  
• Hypovolemic status 
• Ascites 
• Abdominal aorta aneurysm 
• Intraabdominal sepsis 
• Bowel obstruction / Tumors  
 
With proper preparation of the patient, with everything in place, procedure 
done under local anesthesia which involves the following steps: 
PROCEDURE: 
• Pre procedure VAS is obtained. 
• Premedication with Inj.Pentazocine and Inj.Atropine  
• Patient is positioned supine.  
• A surface marker is placed over the patient abdomen at T12 to L2 level.  
• A NECT abdomen is performed.  
• Celiac artery and celiac plexus are localized and the best axial slice selected. 
• The puncture sites are then selected. The surface marker gives the long axis 
and the CT machine lazer beam of the axial slice gives the horizontal axis.  
• From the point of entry, the trajectory is planned (which is the third axis) on 
the console and depth measured. 
• Patient abdomen is painted with povidone iodine and draped. 
• Skin and the anterior abdominal wall infiltrated with 2% lignocaine on both 
sides. 
• Puncture site incision is made with 11 surgical blade. 
• 20G Chiba or Spinal needle is passed from the puncture site along the 
trajectory up to the target site, the antecrural space, bilaterally. 
• The needle tip is first located with the tip artefact. A negative suction helps to 
rule out intra arterial placement of needle tip.  
• Then a mixture of 3 ml of 2% lignocaine with 1ml of contrast is injected on 
each side. In this mixture, lignocaine serves two purposes. First, it assesses 
the needle tip by evaluating the spread. Second, the injected lignocaine, if 
produces mild reduction in pain, warrants a successful outcome.  
• Contrast is added to the mixture, to facilitate the spread of the injected liquid 
in the target space. As the HU of ethyl alcohol is -210 units, like that of 
surrounding Fat, its spread cannot be assessed, if it is injected separately. 
• Once this is confirmed, a mixture of 15 ml of neurolytic agent (Absolute 
alcohol) and 5 ml of 2% lignocaine is injected on each side. It is important to 
rule out intra arterial injection by applying negative suction. As the HU of 
alcohol is  - 210  units, its spread can be appreciated only by means of 
hydrodissection. Lignocaine is added to alleviate any transient pain, 
associated with alcohol injection and for immediate neurolytic effect. 
• The needles are then removed (Before withdrawing, the needles are flushed 
with saline to prevent spillage of alcohol in the trajectory which is painful) 
and hemostasis secured with manual pressure if needed and adhesives 
applied. 
• Immediate post procedure pain evaluation with VAS is obtained on the table. 
 POST PROCEDURE CARE: 
• Patient is shifted to the ward and advised strict bed rest for 12 hours 
• Regular monitoring of vitals is done. 
• Proper hydration with intravenous fluids. 
• Patient can resume normal diet immediately after the procedure. 
• A complete neurological examination done at 24 hours post procedure. 
• A post procedure pain score – VAS score is obtained at 24 hours. 
• Follow up VAS score obtained at 1 week, 1 month and 2 months. 
 
CONCLUSION: 
1) Mean percentage reduction of pain intensity between preprocedure VAS 
score and Immediate post procedure VAS score, immediate post procedure 
and 24 hours score, 24 hours and 1 week score and preprocedure and 2 
months score are 55%, 32%, 31% and 80% respectively, all of which were 
statistically significant. 
2) The pain intensity score remained static from 1 week to 2 months post 
procedure. 
3) Gender does not have any statistical significance in the VAS scores or in 
the response to procedure. 
4) For preprocedure VAS score, the mean difference in within subject 
analysis is statistically significant for preprocedure VAS and immediate 
post procedure score. 
5) There is difference in the Variances of differences between all possible 
pairs of groups with statistical significance indicating, there is a true 
reduction in pain intensity post procedure. 
6) Procedure was more effective for malignancies than inflammatory 
condition. 
7) Maximum percentage reduction in pain, of 88% was seen with pancreatic 
carcinoma. 
8) Least percentage reduction in pain, of 74% was seen with Chronic 
pancreatitis. 
9)  Hypotension was the commonest complication seen in 18 patients (9 
males and 9 females). All these patients settled with intravenous fluids.  
10) Back pain was the second most common complication, seen in 14 
patients (6 males and 8 females).  
11) Shoulder pain was seen in 12 patients (6 males and 6 females). 
12) Absence of pain relief was not reported in this study. 
13) Complications were independent of Gender and Difference VAS 
score. 
14) Complications were dependent on Age with statistical significance. 
 
LIMITATIONS: 
1) Sample size is only 30. 
2) Number of patients in each disease type are not equal and also too 
small in the third and fourth type and hence the results cannot be 
generalised. 
3) Follow up is done only up to 2 months. Hence the long term benefits or 
worsening of pain beyond 2 months is not known. 
 
 
KEY WORDS : 
CELIAC PLEXUS, INTRACTABLE PAIN, ANTERIOR APPROACH, 
NEUROLYTIC AGENT, ABSOLUTE ALCOHOL, VISUAL ANALOG 
SCALE. 
 
ABSTRACT 
 
A prospective study involving 30 patients, diagnosed to have intractable 
upper abdomen pain due to malignancies/ pathologies of inoperable status at 
BARNARD INSTITUTE OF RADIOLOGY, MADRAS MEDICAL COLLEGE & 
RAJIV GANDHI GOVT GENERAL HOSPITAL, CHENNAI by Dr. H. 
Iyengaran, III year M.D.R.D. resident, as the principal investigator under the 
guidance of  Professor S. Kalpana, M.D., D.M.R.D,. These patients were referred 
from the Institute of Anesthesiology and Critical care and from Department of 
Gastroenterology.  
AIMS AND OBJECTIVES: 
• To perform CT guided neurolysis of the CELIAC PLEXUS, through anterior 
approach in patients with intractable upper abdominal pain due to 
intraabdominal malignancies/pathologies of inoperable status. 
• To assess treatment success by evaluating pain relief using Visual Analog 
Scale (VAS) before and after the procedure. 
• To assess minor/major complications associated with the procedure.  
 
The procedure was done through anterior approach with Absolute alcohol as 
the neurolytic agent. Pain assessment was done using Visual Analog scale. 
 
INDICATIONS: 
• Patients with persistent and intractable upper abdominal pain due to 
malignancies / Chronic Pancreatitis of inoperable status 
• Patients with severe nausea and hyperemesis due to Pancreatic cancer  
• In visceral neuropathy in patients with diabetes, Inflammatory bowel disease 
(Crohn’s disease) and sclerosing cholangitis of AIDS. 
 
CONTRAINDICATIONS: 
• Coagulopathies  
• Hypovolemic status 
• Ascites 
• Abdominal aorta aneurysm 
• Intraabdominal sepsis 
• Bowel obstruction / Tumors  
 
With proper preparation of the patient, with everything in place, procedure 
done under local anesthesia which involves the following steps: 
PROCEDURE: 
• Pre procedure VAS is obtained. 
• Premedication with Inj.Pentazocine and Inj.Atropine  
• Patient is positioned supine.  
• A surface marker is placed over the patient abdomen at T12 to L2 level.  
• A NECT abdomen is performed.  
• Celiac artery and celiac plexus are localized and the best axial slice selected. 
• The puncture sites are then selected. The surface marker gives the long axis 
and the CT machine lazer beam of the axial slice gives the horizontal axis.  
• From the point of entry, the trajectory is planned (which is the third axis) on 
the console and depth measured. 
• Patient abdomen is painted with povidone iodine and draped. 
• Skin and the anterior abdominal wall infiltrated with 2% lignocaine on both 
sides. 
• Puncture site incision is made with 11 surgical blade. 
• 20G Chiba or Spinal needle is passed from the puncture site along the 
trajectory up to the target site, the antecrural space, bilaterally. 
• The needle tip is first located with the tip artefact. A negative suction helps to 
rule out intra arterial placement of needle tip.  
• Then a mixture of 3 ml of 2% lignocaine with 1ml of contrast is injected on 
each side. In this mixture, lignocaine serves two purposes. First, it assesses 
the needle tip by evaluating the spread. Second, the injected lignocaine, if 
produces mild reduction in pain, warrants a successful outcome.  
• Contrast is added to the mixture, to facilitate the spread of the injected liquid 
in the target space. As the HU of ethyl alcohol is -210 units, like that of 
surrounding Fat, its spread cannot be assessed, if it is injected separately. 
• Once this is confirmed, a mixture of 15 ml of neurolytic agent (Absolute 
alcohol) and 5 ml of 2% lignocaine is injected on each side. It is important to 
rule out intra arterial injection by applying negative suction. As the HU of 
alcohol is  - 210  units, its spread can be appreciated only by means of 
hydrodissection. Lignocaine is added to alleviate any transient pain, 
associated with alcohol injection and for immediate neurolytic effect. 
• The needles are then removed (Before withdrawing, the needles are flushed 
with saline to prevent spillage of alcohol in the trajectory which is painful) 
and hemostasis secured with manual pressure if needed and adhesives 
applied. 
• Immediate post procedure pain evaluation with VAS is obtained on the table. 
 POST PROCEDURE CARE: 
• Patient is shifted to the ward and advised strict bed rest for 12 hours 
• Regular monitoring of vitals is done. 
• Proper hydration with intravenous fluids. 
• Patient can resume normal diet immediately after the procedure. 
• A complete neurological examination done at 24 hours post procedure. 
• A post procedure pain score – VAS score is obtained at 24 hours. 
• Follow up VAS score obtained at 1 week, 1 month and 2 months. 
 
CONCLUSION: 
1) Mean percentage reduction of pain intensity between preprocedure VAS 
score and Immediate post procedure VAS score, immediate post procedure 
and 24 hours score, 24 hours and 1 week score and preprocedure and 2 
months score are 55%, 32%, 31% and 80% respectively, all of which were 
statistically significant. 
2) The pain intensity score remained static from 1 week to 2 months post 
procedure. 
3) Gender does not have any statistical significance in the VAS scores or in 
the response to procedure. 
4) For preprocedure VAS score, the mean difference in within subject 
analysis is statistically significant for preprocedure VAS and immediate 
post procedure score. 
5) There is difference in the Variances of differences between all possible 
pairs of groups with statistical significance indicating, there is a true 
reduction in pain intensity post procedure. 
6) Procedure was more effective for malignancies than inflammatory 
condition. 
7) Maximum percentage reduction in pain, of 88% was seen with pancreatic 
carcinoma. 
8) Least percentage reduction in pain, of 74% was seen with Chronic 
pancreatitis. 
9)  Hypotension was the commonest complication seen in 18 patients (9 
males and 9 females). All these patients settled with intravenous fluids.  
10) Back pain was the second most common complication, seen in 14 
patients (6 males and 8 females).  
11) Shoulder pain was seen in 12 patients (6 males and 6 females). 
12) Absence of pain relief was not reported in this study. 
13) Complications were independent of Gender and Difference VAS 
score. 
14) Complications were dependent on Age with statistical significance. 
 
LIMITATIONS: 
1) Sample size is only 30. 
2) Number of patients in each disease type are not equal and also too 
small in the third and fourth type and hence the results cannot be 
generalised. 
3) Follow up is done only up to 2 months. Hence the long term benefits or 
worsening of pain beyond 2 months is not known. 
 
 
KEY WORDS : 
CELIAC PLEXUS, INTRACTABLE PAIN, ANTERIOR APPROACH, 
NEUROLYTIC AGENT, ABSOLUTE ALCOHOL, VISUAL ANALOG 
SCALE. 
 
ABSTRACT 
 
A prospective study involving 30 patients, diagnosed to have intractable 
upper abdomen pain due to malignancies/ pathologies of inoperable status at 
BARNARD INSTITUTE OF RADIOLOGY, MADRAS MEDICAL COLLEGE & 
RAJIV GANDHI GOVT GENERAL HOSPITAL, CHENNAI by Dr. H. 
Iyengaran, III year M.D.R.D. resident, as the principal investigator under the 
guidance of  Professor S. Kalpana, M.D., D.M.R.D,. These patients were referred 
from the Institute of Anesthesiology and Critical care and from Department of 
Gastroenterology.  
AIMS AND OBJECTIVES: 
• To perform CT guided neurolysis of the CELIAC PLEXUS, through anterior 
approach in patients with intractable upper abdominal pain due to 
intraabdominal malignancies/pathologies of inoperable status. 
• To assess treatment success by evaluating pain relief using Visual Analog 
Scale (VAS) before and after the procedure. 
• To assess minor/major complications associated with the procedure.  
 
The procedure was done through anterior approach with Absolute alcohol as 
the neurolytic agent. Pain assessment was done using Visual Analog scale. 
 
INDICATIONS: 
• Patients with persistent and intractable upper abdominal pain due to 
malignancies / Chronic Pancreatitis of inoperable status 
• Patients with severe nausea and hyperemesis due to Pancreatic cancer  
• In visceral neuropathy in patients with diabetes, Inflammatory bowel disease 
(Crohn’s disease) and sclerosing cholangitis of AIDS. 
 
CONTRAINDICATIONS: 
• Coagulopathies  
• Hypovolemic status 
• Ascites 
• Abdominal aorta aneurysm 
• Intraabdominal sepsis 
• Bowel obstruction / Tumors  
 
With proper preparation of the patient, with everything in place, procedure 
done under local anesthesia which involves the following steps: 
PROCEDURE: 
• Pre procedure VAS is obtained. 
• Premedication with Inj.Pentazocine and Inj.Atropine  
• Patient is positioned supine.  
• A surface marker is placed over the patient abdomen at T12 to L2 level.  
• A NECT abdomen is performed.  
• Celiac artery and celiac plexus are localized and the best axial slice selected. 
• The puncture sites are then selected. The surface marker gives the long axis 
and the CT machine lazer beam of the axial slice gives the horizontal axis.  
• From the point of entry, the trajectory is planned (which is the third axis) on 
the console and depth measured. 
• Patient abdomen is painted with povidone iodine and draped. 
• Skin and the anterior abdominal wall infiltrated with 2% lignocaine on both 
sides. 
• Puncture site incision is made with 11 surgical blade. 
• 20G Chiba or Spinal needle is passed from the puncture site along the 
trajectory up to the target site, the antecrural space, bilaterally. 
• The needle tip is first located with the tip artefact. A negative suction helps to 
rule out intra arterial placement of needle tip.  
• Then a mixture of 3 ml of 2% lignocaine with 1ml of contrast is injected on 
each side. In this mixture, lignocaine serves two purposes. First, it assesses 
the needle tip by evaluating the spread. Second, the injected lignocaine, if 
produces mild reduction in pain, warrants a successful outcome.  
• Contrast is added to the mixture, to facilitate the spread of the injected liquid 
in the target space. As the HU of ethyl alcohol is -210 units, like that of 
surrounding Fat, its spread cannot be assessed, if it is injected separately. 
• Once this is confirmed, a mixture of 15 ml of neurolytic agent (Absolute 
alcohol) and 5 ml of 2% lignocaine is injected on each side. It is important to 
rule out intra arterial injection by applying negative suction. As the HU of 
alcohol is  - 210  units, its spread can be appreciated only by means of 
hydrodissection. Lignocaine is added to alleviate any transient pain, 
associated with alcohol injection and for immediate neurolytic effect. 
• The needles are then removed (Before withdrawing, the needles are flushed 
with saline to prevent spillage of alcohol in the trajectory which is painful) 
and hemostasis secured with manual pressure if needed and adhesives 
applied. 
• Immediate post procedure pain evaluation with VAS is obtained on the table. 
 POST PROCEDURE CARE: 
• Patient is shifted to the ward and advised strict bed rest for 12 hours 
• Regular monitoring of vitals is done. 
• Proper hydration with intravenous fluids. 
• Patient can resume normal diet immediately after the procedure. 
• A complete neurological examination done at 24 hours post procedure. 
• A post procedure pain score – VAS score is obtained at 24 hours. 
• Follow up VAS score obtained at 1 week, 1 month and 2 months. 
 
CONCLUSION: 
1) Mean percentage reduction of pain intensity between preprocedure VAS 
score and Immediate post procedure VAS score, immediate post procedure 
and 24 hours score, 24 hours and 1 week score and preprocedure and 2 
months score are 55%, 32%, 31% and 80% respectively, all of which were 
statistically significant. 
2) The pain intensity score remained static from 1 week to 2 months post 
procedure. 
3) Gender does not have any statistical significance in the VAS scores or in 
the response to procedure. 
4) For preprocedure VAS score, the mean difference in within subject 
analysis is statistically significant for preprocedure VAS and immediate 
post procedure score. 
5) There is difference in the Variances of differences between all possible 
pairs of groups with statistical significance indicating, there is a true 
reduction in pain intensity post procedure. 
6) Procedure was more effective for malignancies than inflammatory 
condition. 
7) Maximum percentage reduction in pain, of 88% was seen with pancreatic 
carcinoma. 
8) Least percentage reduction in pain, of 74% was seen with Chronic 
pancreatitis. 
9)  Hypotension was the commonest complication seen in 18 patients (9 
males and 9 females). All these patients settled with intravenous fluids.  
10) Back pain was the second most common complication, seen in 14 
patients (6 males and 8 females).  
11) Shoulder pain was seen in 12 patients (6 males and 6 females). 
12) Absence of pain relief was not reported in this study. 
13) Complications were independent of Gender and Difference VAS 
score. 
14) Complications were dependent on Age with statistical significance. 
 
LIMITATIONS: 
1) Sample size is only 30. 
2) Number of patients in each disease type are not equal and also too 
small in the third and fourth type and hence the results cannot be 
generalised. 
3) Follow up is done only up to 2 months. Hence the long term benefits or 
worsening of pain beyond 2 months is not known. 
 
 
KEY WORDS : 
CELIAC PLEXUS, INTRACTABLE PAIN, ANTERIOR APPROACH, 
NEUROLYTIC AGENT, ABSOLUTE ALCOHOL, VISUAL ANALOG 
SCALE. 
 
ABSTRACT 
 
A prospective study involving 30 patients, diagnosed to have intractable 
upper abdomen pain due to malignancies/ pathologies of inoperable status at 
BARNARD INSTITUTE OF RADIOLOGY, MADRAS MEDICAL COLLEGE & 
RAJIV GANDHI GOVT GENERAL HOSPITAL, CHENNAI by Dr. H. 
Iyengaran, III year M.D.R.D. resident, as the principal investigator under the 
guidance of  Professor S. Kalpana, M.D., D.M.R.D,. These patients were referred 
from the Institute of Anesthesiology and Critical care and from Department of 
Gastroenterology.  
AIMS AND OBJECTIVES: 
• To perform CT guided neurolysis of the CELIAC PLEXUS, through anterior 
approach in patients with intractable upper abdominal pain due to 
intraabdominal malignancies/pathologies of inoperable status. 
• To assess treatment success by evaluating pain relief using Visual Analog 
Scale (VAS) before and after the procedure. 
• To assess minor/major complications associated with the procedure.  
 
The procedure was done through anterior approach with Absolute alcohol as 
the neurolytic agent. Pain assessment was done using Visual Analog scale. 
 
INDICATIONS: 
• Patients with persistent and intractable upper abdominal pain due to 
malignancies / Chronic Pancreatitis of inoperable status 
• Patients with severe nausea and hyperemesis due to Pancreatic cancer  
• In visceral neuropathy in patients with diabetes, Inflammatory bowel disease 
(Crohn’s disease) and sclerosing cholangitis of AIDS. 
 
CONTRAINDICATIONS: 
• Coagulopathies  
• Hypovolemic status 
• Ascites 
• Abdominal aorta aneurysm 
• Intraabdominal sepsis 
• Bowel obstruction / Tumors  
 
With proper preparation of the patient, with everything in place, procedure 
done under local anesthesia which involves the following steps: 
PROCEDURE: 
• Pre procedure VAS is obtained. 
• Premedication with Inj.Pentazocine and Inj.Atropine  
• Patient is positioned supine.  
• A surface marker is placed over the patient abdomen at T12 to L2 level.  
• A NECT abdomen is performed.  
• Celiac artery and celiac plexus are localized and the best axial slice selected. 
• The puncture sites are then selected. The surface marker gives the long axis 
and the CT machine lazer beam of the axial slice gives the horizontal axis.  
• From the point of entry, the trajectory is planned (which is the third axis) on 
the console and depth measured. 
• Patient abdomen is painted with povidone iodine and draped. 
• Skin and the anterior abdominal wall infiltrated with 2% lignocaine on both 
sides. 
• Puncture site incision is made with 11 surgical blade. 
• 20G Chiba or Spinal needle is passed from the puncture site along the 
trajectory up to the target site, the antecrural space, bilaterally. 
• The needle tip is first located with the tip artefact. A negative suction helps to 
rule out intra arterial placement of needle tip.  
• Then a mixture of 3 ml of 2% lignocaine with 1ml of contrast is injected on 
each side. In this mixture, lignocaine serves two purposes. First, it assesses 
the needle tip by evaluating the spread. Second, the injected lignocaine, if 
produces mild reduction in pain, warrants a successful outcome.  
• Contrast is added to the mixture, to facilitate the spread of the injected liquid 
in the target space. As the HU of ethyl alcohol is -210 units, like that of 
surrounding Fat, its spread cannot be assessed, if it is injected separately. 
• Once this is confirmed, a mixture of 15 ml of neurolytic agent (Absolute 
alcohol) and 5 ml of 2% lignocaine is injected on each side. It is important to 
rule out intra arterial injection by applying negative suction. As the HU of 
alcohol is  - 210  units, its spread can be appreciated only by means of 
hydrodissection. Lignocaine is added to alleviate any transient pain, 
associated with alcohol injection and for immediate neurolytic effect. 
• The needles are then removed (Before withdrawing, the needles are flushed 
with saline to prevent spillage of alcohol in the trajectory which is painful) 
and hemostasis secured with manual pressure if needed and adhesives 
applied. 
• Immediate post procedure pain evaluation with VAS is obtained on the table. 
 POST PROCEDURE CARE: 
• Patient is shifted to the ward and advised strict bed rest for 12 hours 
• Regular monitoring of vitals is done. 
• Proper hydration with intravenous fluids. 
• Patient can resume normal diet immediately after the procedure. 
• A complete neurological examination done at 24 hours post procedure. 
• A post procedure pain score – VAS score is obtained at 24 hours. 
• Follow up VAS score obtained at 1 week, 1 month and 2 months. 
 
CONCLUSION: 
1) Mean percentage reduction of pain intensity between preprocedure VAS 
score and Immediate post procedure VAS score, immediate post procedure 
and 24 hours score, 24 hours and 1 week score and preprocedure and 2 
months score are 55%, 32%, 31% and 80% respectively, all of which were 
statistically significant. 
2) The pain intensity score remained static from 1 week to 2 months post 
procedure. 
3) Gender does not have any statistical significance in the VAS scores or in 
the response to procedure. 
4) For preprocedure VAS score, the mean difference in within subject 
analysis is statistically significant for preprocedure VAS and immediate 
post procedure score. 
5) There is difference in the Variances of differences between all possible 
pairs of groups with statistical significance indicating, there is a true 
reduction in pain intensity post procedure. 
6) Procedure was more effective for malignancies than inflammatory 
condition. 
7) Maximum percentage reduction in pain, of 88% was seen with pancreatic 
carcinoma. 
8) Least percentage reduction in pain, of 74% was seen with Chronic 
pancreatitis. 
9)  Hypotension was the commonest complication seen in 18 patients (9 
males and 9 females). All these patients settled with intravenous fluids.  
10) Back pain was the second most common complication, seen in 14 
patients (6 males and 8 females).  
11) Shoulder pain was seen in 12 patients (6 males and 6 females). 
12) Absence of pain relief was not reported in this study. 
13) Complications were independent of Gender and Difference VAS 
score. 
14) Complications were dependent on Age with statistical significance. 
 
LIMITATIONS: 
1) Sample size is only 30. 
2) Number of patients in each disease type are not equal and also too 
small in the third and fourth type and hence the results cannot be 
generalised. 
3) Follow up is done only up to 2 months. Hence the long term benefits or 
worsening of pain beyond 2 months is not known. 
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ABSTRACT 
 
A prospective study involving 30 patients, diagnosed to have intractable 
upper abdomen pain due to malignancies/ pathologies of inoperable status at 
BARNARD INSTITUTE OF RADIOLOGY, MADRAS MEDICAL COLLEGE & 
RAJIV GANDHI GOVT GENERAL HOSPITAL, CHENNAI by Dr. H. 
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Gastroenterology.  
AIMS AND OBJECTIVES: 
• To perform CT guided neurolysis of the CELIAC PLEXUS, through anterior 
approach in patients with intractable upper abdominal pain due to 
intraabdominal malignancies/pathologies of inoperable status. 
• To assess treatment success by evaluating pain relief using Visual Analog 
Scale (VAS) before and after the procedure. 
• To assess minor/major complications associated with the procedure.  
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the neurolytic agent. Pain assessment was done using Visual Analog scale. 
 
INDICATIONS: 
• Patients with persistent and intractable upper abdominal pain due to 
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(Crohn’s disease) and sclerosing cholangitis of AIDS. 
 
CONTRAINDICATIONS: 
• Coagulopathies  
• Hypovolemic status 
• Ascites 
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• Intraabdominal sepsis 
• Bowel obstruction / Tumors  
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• Once this is confirmed, a mixture of 15 ml of neurolytic agent (Absolute 
alcohol) and 5 ml of 2% lignocaine is injected on each side. It is important to 
rule out intra arterial injection by applying negative suction. As the HU of 
alcohol is  - 210  units, its spread can be appreciated only by means of 
hydrodissection. Lignocaine is added to alleviate any transient pain, 
associated with alcohol injection and for immediate neurolytic effect. 
• The needles are then removed (Before withdrawing, the needles are flushed 
with saline to prevent spillage of alcohol in the trajectory which is painful) 
and hemostasis secured with manual pressure if needed and adhesives 
applied. 
• Immediate post procedure pain evaluation with VAS is obtained on the table. 
 POST PROCEDURE CARE: 
• Patient is shifted to the ward and advised strict bed rest for 12 hours 
• Regular monitoring of vitals is done. 
• Proper hydration with intravenous fluids. 
• Patient can resume normal diet immediately after the procedure. 
• A complete neurological examination done at 24 hours post procedure. 
• A post procedure pain score – VAS score is obtained at 24 hours. 
• Follow up VAS score obtained at 1 week, 1 month and 2 months. 
 
CONCLUSION: 
1) Mean percentage reduction of pain intensity between preprocedure VAS 
score and Immediate post procedure VAS score, immediate post procedure 
and 24 hours score, 24 hours and 1 week score and preprocedure and 2 
months score are 55%, 32%, 31% and 80% respectively, all of which were 
statistically significant. 
2) The pain intensity score remained static from 1 week to 2 months post 
procedure. 
3) Gender does not have any statistical significance in the VAS scores or in 
the response to procedure. 
4) For preprocedure VAS score, the mean difference in within subject 
analysis is statistically significant for preprocedure VAS and immediate 
post procedure score. 
5) There is difference in the Variances of differences between all possible 
pairs of groups with statistical significance indicating, there is a true 
reduction in pain intensity post procedure. 
6) Procedure was more effective for malignancies than inflammatory 
condition. 
7) Maximum percentage reduction in pain, of 88% was seen with pancreatic 
carcinoma. 
8) Least percentage reduction in pain, of 74% was seen with Chronic 
pancreatitis. 
9)  Hypotension was the commonest complication seen in 18 patients (9 
males and 9 females). All these patients settled with intravenous fluids.  
10) Back pain was the second most common complication, seen in 14 
patients (6 males and 8 females).  
11) Shoulder pain was seen in 12 patients (6 males and 6 females). 
12) Absence of pain relief was not reported in this study. 
13) Complications were independent of Gender and Difference VAS 
score. 
14) Complications were dependent on Age with statistical significance. 
 
LIMITATIONS: 
1) Sample size is only 30. 
2) Number of patients in each disease type are not equal and also too 
small in the third and fourth type and hence the results cannot be 
generalised. 
3) Follow up is done only up to 2 months. Hence the long term benefits or 
worsening of pain beyond 2 months is not known. 
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 AIMS AND OBJECTIVES 
 
• To perform CT guided neurolysis of the CELIAC PLEXUS, through 
anterior approach in patients with intractable upper abdominal pain due to 
intraabdominal malignancies/pathologies of inoperable status. 
 
• To assess treatment success by evaluating pain relief using Visual Analog 
Scale (VAS) before and after the procedure. 
 
• To assess minor/major complications associated with the procedure.  
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The celiac plexus is a large visceral plexus  in the retro peritoneum, 
over the anterior and lateral surface of aorta and around the branching of 
celiac trunk. It serves as a relay centre for pain impulses that arise from the 
upper abdominal viscera 
Treatment for such pain is initially achieved by low dose opiates, a 
narcotic drug. However, with time or with the progression of the disease, 
complications or tolerance set in. It is this group of patients, who can 
benefit from this procedure. 
The first ever blockade of splanchnic nerves in the management of 
upper abdominal pain was done by Kappis in 1919. He used palpable 
bony landmarks as the guide for his procedure.  
Wendling et al described anterior percutaneous approach for 
anesthetizing the celiac plexus and splanchnic nerves. 
 Jones  provided  the first description of ethanol-induced neurolysis 
of the celiac plexus and splanchnic nerves for long-term pain relief.   
  
 CT-guided celiac plexus block, was described by Haaga and 
colleag ues in 1977. It was in the 1950’s that neurolysis under scopic 
guidance was done. This was followed by neurolysis under echographic 
guidance in 1970’s. 
Merrick. R. L (1941) investigated the histologic and cytologic 
changes in the autonomic nerves and ganglia following alcohol injection in 
cats. The lumbar sympathetic ganglia and rami were used for the study of 
degeneration and regeneration of ganglion cells and postganglionic fibres 
following nerve block. He concluded that the changes which occur after 
infiltration of a ganglion differ from those which occur after infiltration of 
the rami. When a ganglion is infiltrated, a permanent block to all effectors 
innervated by the post ganglionic fibres taking origin from it, is produced, 
since the alcohol kills the ganglion cells. When the rami alone are 
infiltrated, a temporary block is produced. In order to produce permanent 
sympathetic nerve block by means of paravertebral alcohol injection, the 
ganglia must be infiltrated. Destruction  of the ganglia was was seen only 
when the alcohol was injected in the immediate vicinity. In some cases, 
only the rami were infiltrated, even though alcohol was injected close to 
the ganglia. In other cases, the infiltration was not sufficiently extensive to 
destroy all the ganglion cells. These results indicate that the point of the 
needle must be practically adjacent to the ganglia in order to ensure 
 complete infiltration. On the other hand, block of the rami is accomplished 
very easily. The variability of the results obtained by paravertebral 
injection in clinical cases may be explained at least in part on this basis. 
Gregg  R. V. et al (1985) studied the optimal concentration or range 
of concentrations of ethyl alcohol which produces neurolysis 
experimentally on the peripheral nerves of a cat. They conducted studies 
with normal saline (control), 50 %, 75% or 100% ethyl alcohol with 
normal saline as the diluents and concluded that any of these 
concentrations of alcohol can be neurolytic. However larger area of 
destruction was observed with higher ethyl alcohol concentration along 
with the variable spread of the neurolytic. At eight weeks interval, they 
found evidence of neurolysis. This is important for prolonged pain relief 
after neurolytic procedures. 
Wang et al reported that the diagnostic feature of a celiac ganglion is 
the presence of persistent contrast enhancement on delayed images (10 
minutes), which is recognized by increased attenuation compared with that 
of the adrenals. 
Zhang et al reported that the right ganglion is mostly located at the 
superior angle formed by the entrance of the left renal vein into the IVC 
and is partly or completely covered by the IVC 
 Zhang XM, Zhao QH, Zeng NL, et al demonstrated The celiac 
ganglia: anatomy using MRI in cadavers 
Kambadakone et al reported that the two most important factors 
that affect destruction of the celiac plexus are the amount of neurolytic 
agent injected and the degree of diffusion of the neurolytic agent in the 
antecrural space 
Montero Matamala A, achieved pain relief of 80% of the cases after 
2 weeks and in 60% after 6 months with no serious complications in 
percutaneous anterior approach using CT guidance. 
Jill. C. Moore – Journal of supportive oncology reported that Regardless 
of the technique used, CPN has a long lasting benefit in up to 70 % t0 90% 
of patients with pancreatic cancer.  
Wang et al described a technique in which the neurolytic agent is 
directly injected into a tumor mass in the retropancreatic space, in patients 
whose retropancreatic space is completely occupied by a primary tumor or 
metastatic lymphadenopathy, called Direct Tumor infiltration 
Lieberman RP, Waldman SD. Celiac plexus neurolysis with the 
modified transaortic approach 
 Puli SR, Reddy JB, Bechtold ML, Antillon MR, 
Brugge WR. EUS-guided celiac plexus neurolysis for pain due to chronic 
pancreatitis or pancreatic cancer pain 
Burton AW. And Yan BM, Myers RP Neurolytic celiac plexus 
block offers improved pain control, reduces the amount of narcotic 
analgesics, and has a lower incidence of constipation than standard 
treatment 
Ischia S, Ischia A, Polati E, Finco G. Three posterior percutaneous 
celiac plexus block techniques. A prospective, randomized study in 61 
patients with pancreatic cancer pain reported that the major benefit of 
celiac plexus neurolysis is in the reduced rate of analgesic consumption 
and lower incidence of drug-related adverse effects 
B. Kastler – Interventional Radiology in pain treatment states that 
In the case of pain secondary to an inflammatory pathology, in particular 
chronic pancreatitis, upon which the efficacy of celiac neurolysis is 
reduced,the sit- uation seems totally different 
Noble M,  Gress  FG. Techniques and results of neurolysis for 
chronic pancreatitis and pancreatic cancer pain – reported that the 
procedure was less effective in chronic pancreatitis compared to pancreatic 
cancer. 
  Gress F, Schmitt C, Sherman S, Ikenberry S, Lehman G. A 
prospective randomized comparison of endoscopic ultrasound– and 
computed tomography–guided celiac plexus block for managing chronic 
pancreatitis pain reported that the role of celiac plexus neurolysis in 
patients with refractory abdominal pain resulting from chronic pancreatitis 
is not well established with temporary relief in some patients 
C. Moore reported that Local pain, diarrhea, and transient 
hypotension are often seen complications 
Gafanovich I, Shir Y, Tsvang E, Ben-Chetrit E. demonstrated 
Chronic diarrhoea as a complication induced by celiac plexus block 
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Magic and pain were considered to be similar during the primitive 
years. An evil spirit was apparently considered to be the cause of pain and 
sufferings of a man. It became habitual to make an enchanter inflict a 
wound to the victim to banish the troubling spirit. 
Ancient Greeks (including  jomer), Hebrews and Egyptians believed 
the agony as an indication of god. Hippocrates tried to discard the spiritual 
aura on pain by his popular formula “Divine is the work of relieving pain” 
in the 400BC. 
Since then the concept and the understanding of pain kept changing 
from time to time. Pain was considered as an emotion instead of a 
sensation by Aristotle and Plato. In the new awakening, Lorenzo de Medici 
and his Academy influenced the appearance of modern anatomic and 
physiological perception of pain. It was now a sensation overseen by the 
nervous system rather than an emotion. 
Vesalius, Pare, and Paracelsus are the great names of medicine to be 
recalled forever. Pare: was the first to ligature blood vessels and Descartes 
investigated the mystic trouble of pain in the “ghost limb”. 
 The battle against pain and advancement in pharmacology made the 
18th and 19th centuries important. Laudanum was formulated by Sydenham 
in 1750.Sertuener began using morphine in Hanover. 
Discoveries were numerous: nitrogen dioxide was identified by 
Priestley in the 1770s and made use of by Davy in the 1840s; ether was 
described by Faraday in 1818 and used by Hickman in the 1830s; 
chloroform was simultaneously found by Von Liebig in Germany, 
Soubeiran in France, and Guthrie in the USA.  
The first general anesthesia was performed by Morton on October 
16, 1846, in Boston, MA, USA, (the word anesthesia having been 
suggested by Oliver Wendell Holmes). While surgeons did not corroborate 
the idea of general anesthesia at the start, they had to give up their ideas 
with the tremendous advancement fetched by anesthesia.  
John Bonica, defined the concept of “pain clinics” and in 1973 he 
founded the International Association for the Study of Pain (IASP). 
The problem specifies by IASP falls out as: “Pain is an unpleasant 
sensory and emotional experience, connected with an existing or potential 
tissue lesion, or described in terms of such a lesion.” Two advantages are 
drawn out from the definition: 
 1) Pain is believed as a central neuro-physio-psychological outcome with a 
dual proportion, a immanent one, sensory and an emotional one, which can 
be measured only by the sick individual by its displeasing character. 
2) It vindicates the terrible moan of a mental disorder, as it emphasizes the 
fact that pain yielding mechanisms may have a psychological basis in 
addition to the physical one. 
 
CLASSIFICATION OF PAIN –  
Pain can be classified based on its duration or physiopathology. 
I ) Based on its duration pain can be either acute or chronic 
II ) Based on physiopathology pain is of 3 types –  
A ) Pain on account of Excess Nociperception 
B) Neurogenic Pain 
C ) Hysterical Pain 
Chronic pain syndrome-  
 It is quite common, to see People suffering  from pain, over a long 
duration of time  presenting with a vast number of symptoms and signs 
which is referred to as chronic pain syndrome. 
 F.Bourreau  defines CPS as a band of psychological, physiological 
behavioural and social signs which persuade us to see pain ,irrespective of 
its original etiology, more as an ’illness in itself’ instead of the bare 
symptom of an inherent physiopathological disorder. 
Patients suffering from CPS can be grouped into two –  
I ) CPS  with a dominant organic component   
II ) CPS with a dominant psychological component 
  It is important to determine what component dominates the 
individual before offering any treatment. However, as both organic and 
psychological components are present in all individuals, it is important to 
address each of these components for a better outcome. 
TREATMENT OF PAIN –  
With the advent of medicines, the treatment of pain has gone a long 
way. Treatment can be by medicinal or non-medicinal therapies. Each 
therapy has its own indications, effects and side effects. 
A ) MEDICINAL TREATMENT- 
I ) Non-narcotic Analgesics 
II ) Narcotic Analgesics 
 
 Undesirable Effects of Narcotics  
• Constipation,  
• Nausea, vomiting  
• Sedation and somnolence 
• Urinary retention 
• Respiratory depression   
B ) NON-MEDICINAL THERAPIES 
 Peripheral Analgesic Stimulations 
 Transcutaneous Neurostimulation 
 Acupuncture 
 Physical Technics- vibrotherapy, massage, electrotherapy, 
thermotherapy, immobilization and tractions Cryotherapy, 
C ) PAIN SURGERY 
I ) Techniques that Break into the Paths of Pain 
A direct surgical approach has progressively been replaced by less 
invasive as well as more selective techniques:  
 Percutaneous neurolyses and sympatholyses (destruction of 
skeletal and sympathetic nerve fibres)  
  Thermocoagulation admitting neurolysis with the heat 
inducted by an electrode adjoined with the aimed nerve 
 Posterior rhizotomy, the most previous(1889) and a 
technique  used to the lowest degree. 
 Anterolateral cordotomy 
II ) Techniques of Retro-pain Control 
III ) Intracerebral and Intrarachnoid Narcotic Therapy 
IV ) INTERVENTIONAL RADIOLOGY 
A magnificent advancement has been seen in the arena of Intervention 
  Radiology in the management of pain. The prime indications include 
Infiltration and neurolysis of the sphenopalatine and stellate ganglion, 
Neurolysis of the mandibular nerve, Thoracic sympatholysis, Neurolysis of 
the celiac plexus, Neurolysis of the sympathetic internal iliac plexus and of 
the unpaired plexus, Infiltration of the pudendal nerve, Infiltration,block,or 
ablation of a nerve root, Treatment under TDM control of osteoid osteoma 
and  Radiofrequency ablation or tumoral alcoholization,  
To conclude, we have come a long way as far as the concepts and 
understanding of pain are concerned.  Treatment of pain is a 
multidisciplinary approach which has to be catered to each individual 
considering every possible component of pain. 
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 CELIAC PLEXUS NEUROLYSIS 
- RATIONALE 
 
CELIAC PLEXUS NEUROLYSIS – what is the need for this procedure? 
   
  The celiac plexus is a large visceral plexus which is situated in the 
retro peritoneum at a deeper level, over the anterior and lateral surface of 
aorta and around the branching of celiac trunk from the aorta. It serves as a 
relay centre for pain impulses that arise from the upper abdominal viscera 
which includes from the stomach cranially to the proximal transverse colon 
caudally.  
Treatment for such pain  is initially achieved by low dose opiates, a 
narcotic drug. However, with time or with the progression of the disease, 
there is a need for escalation of the dose of the drugs. With increased dose 
of opiates, patients experience adverse effects like constipation, nausea, 
vomiting, somnolence and urinary retention limiting its use, thereby poor 
control of pain. 
 Celiac plexus neurolysis, with lytic agents like ethanol or phenol, is 
an effective means of reducing pain that arises from the structures 
involved. Percutaneous image guided celiac plexus neurolysis is an 
 important treatment option for the management of patients with intractable 
abdominal pain due to upper abdominal malignancy.  
Celiac plexus neurolysis helps only to diminish the intensity of pain 
and does not completely abolish pain. However the reduction in pain is 
helpful in reducing opioid requirements thereby reducing the incidence of 
related side effects and improving survival in patients with intractable pain 
due to upper abdominal malignancy. 
The effect on the celiac plexus can be a simple block or complete 
lysis. Celiac plexus block is temporary blockage of transmission of pain 
through the celiac plexus. It is achieved by infiltrating steroids or 
prolonged local anesthetics. Celiac plexus neurolysis, or neurolytic celiac 
plexus block, is permanent lysis of the celiac plexus by injecting ethanol or 
phenol 
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Definition 
The international association for the study of pain (IASP) defined 
Pain as an unpleasant sensory and emotional experience, connected with an 
existing or potential tissue lesion, or described in terms of such a lesion. 
 
RECEPTORS AND PATHWAYS OF PAIN  
Somatic pain 
The sense organs for pain are the naked nerve endings found in 
almost every tissue of the body. Pain impulses are transmitted to the 
central nervous system by two fibre systems. One nociceptor system is 
made up of small myelinated Aδ fibres and the other consists of 
unmyelinated C fibres.  
The conduction velocity of Aδ fibres is 12 – 30 m/s and that of C 
fibres is 0.5 – 2 m/s. Both fibre groups end in the dorsal horn.  Aδ fibres 
terminate primarily in neurons in lamina 1 and 5 whereas dorsal root C 
 fibre on neurons in lamina 1 and 2. The synaptic transmitter secreted by 
primary afferent fibres subserving pain is Substance P. 
Some of the axons of the dorsal horn neurons end in the spinal cord 
and brain stem. Others enter the anterolateral system, including the lateral 
spinothalamic tract.  
A few ascend in the posterolateral portion of the cord. Some of the 
ascending fibres project to the specific sensory nuclei of the thalamus and 
from there to the cerebral cortex. PET and MRI studies in normal humans 
indicate that pain activates three cortical areas namely SI, SII and the 
Cingulate gyrus. The cingulated gyrus is involved in emotion and 
cingulated gyrectomy has been reported to lessen the distress of pain. 
Many fibres activated by pain are in the reticular system, which 
projects to the midline and intralaminar nonspecific projection of nuclei of 
the thalamus and from there to many different parts of the cortex. Others 
project to the hypothalamus and some end in the periaqueductal gray 
matter, an area concerned with pain. 
Visceral pain 
Pain from visceral structures is poorly localized, unpleasant and 
associated with nausea and autonomic symptoms. It often radiates or is 
referred to other areas. 
 The autonomic nervous system, like the somatic, has afferent 
components, central integrating stations and effector pathways. The 
visceral afferent mechanisms play a major role in homeostatic adjustments.  
In the viscera, there are a number of special receptors like 
osmoreceptors, baroreceptors, chemoreceptors etc. that respond to changes 
in the internal environment. The afferent nerves from these receptors make 
reflex connections that are intimately concerned with regulating the 
function of various systems with which they are associated. 
The receptors for pain and the other sensory modalities present in 
the viscera are similar to those in the skin, but there are marked differences 
in their distribution. There are no proprioreceptors in the, and few 
temperature and touch sense organ pain receptors are present, although 
they are more sparsely distributed than in somatic structures. 
Afferent fibres from the visceral structures reach the CNS via 
sympathetic and parasympathetic pathways. Their cell bodies are located 
in the dorsal roots and the homologous cranial nerve ganglia. Specifically, 
there are visceral afferents in the facial, glossopharyngeal and vagus 
nerves; in the lower thoracic and upper lumbar dorsal root; and in the 
sacral roots. 
 There may also be visceral afferent fibres from the eye in the 
trigeminal nerve. Visceral sensation travels along the same pathways as 
somatic sensation in the spinothalamic tracts and thalamic radiations, and 
the cortical receiving areas for visceral sensation are intermixed with the 
somatic receiving areas in the postcentral gyri. 
 
ROLE OF AUTONOMIC NERVOUS SYSTEM IN PAIN  
 
The autonomic nervous system is a complexly connected system 
which automatically regulates organ function to an organisms needs. 
Through numerous connections with sensory, motor and limbic apparatus, 
the ANS influences the voluntary nervous system. 
Functionally and anatomically there are three organizational levels 
that can be differentiated in autonomic nervous system. 
The highest level is the diencephalon and reticular formation, which 
control and regulate the function of target systems. The second level is 
divided into sympathetic and parasympathetic system. These systems are 
closely linked and antagonistic in their effect on the target systems. The 
peripheral intramural system is under the control of central autonomic 
feedback but can act autonomously within limits. 
 The significance of the autonomic functional disorders, the 
involvement of the sympathetic and parasympathetic systems in pathologic 
changes are often ignored even though the autonomic nervous system is 
extensively involved in all body reactions and disease. This is especially 
true for acute and chronic pain. 
 
Organization of the Sympathetic Nervous System – 
 
The cell bodies of the preganglionic sympathetic fibres are located 
in the thoracic and lumbar segments of the spinal cord. In this area, the 
sympathetic trunk has a rigorous segmental structure, that is one segment 
consists of one dermatome, myotome, enterotome, angitome, sclerotome, 
etc... 
The preganglionic sympathetic fibres exit from the spinal cord via 
the anterior root, along with the efferent fibres of the peripheral nerve. 
After leaving the anterior root, they are called white communicating 
branches (medullated nerve fibres) and extend to the paired sympathetic 
trunk (trunkus sympathicus) on both sides of the vertebral bodies.  
The sympathetic trunk extends from the base of the skull to the 
coccyx. On each side of the trunk, there are approximately 22 sympathetic 
 trunk ganglia which are interconnected by interganglionic branches. In the 
neck there are large ganglia namely superior, middle and inferior cervical 
ganglion. In the thoraco-lumbar region, the sympathetic trunk is in a 
rigorous metameric structure. Caudally there exist four sacral pairs of 
ganglia and a single rudimentary coccygeal ganglion. 
A part of the preganglionic fibres traverse, either ascending or 
descending through the interganglionic branches without forming synapses 
through several sympathetic trunk ganglia. They then synapse with the 
postganglionic neurons. This means that the experimental or therapeutic 
stimulation of a single preganglionic neuron can affect up to eight 
dermatomes, angiotomes etc., whereas the stimulation of a postganglionic 
neuron will affect only one segment. 
Another group of the prepreganglionic sympathetic fibres passes 
through the sympathetic trunk ganglion without synapsing and leaves the 
ganglion as the splanchnic nerves. The splanchnic nerves extend to the 
unpaired prevertebral ganglion and intramural plexus. There they synapse 
and form the post ganglionic neurons.  
Located in the region of the ganglia there are always autonomic 
plexi. These plexi are predominantly in the region of the lung hilus, heart 
and large vessels (cardiac, pulmonary, celiac etc). All preganglionic 
neurons for the thoracic region originate between C8 and T5. Furthermore 
 all fibres for the abdominal and pelvic organs originate between T5 and 
L2.  
The post ganglionic fibres of the abdominal and pelvic organs begin 
from plexi and do not travel with the segmental nerves, but with the 
vessels to the intramural plexi as periadventitial reticulum.  
Wall and Melzack in their classic treatise on pain have enumerated 
on the basic scientific evidence for the role of the sympathetic nervous 
system in pain.  
• After nerve injury, interactions have been shown to occur between the 
sensory system and the sympathetic system at the level of the dorsal root 
ganglion. It has been shown experimentally also that there is cross 
excitation between nerves of all sizes after injury via synapses. 
• After nerve injury adjacent functioning nerves also become weakly 
sensitive to circulating catecholamines. 
• Inflammation related pain may also receive contributions from the 
sympathetic system. Surgical or chemical sympathectomy has been found 
to reduce plasma extravasation induced by bradykinin or serotonin 
 
 
 
  
 
 
 
ANATOMYANDPHYSIOLOGY 
OF 
CELIAC PLEXUS 
 
 
 
 
 ANATOMY AND PHYSIOLOGY 
OF CELIAC PLEXUS 
 
The celiac plexus is a large visceral plexus which is situated in the 
retro peritoneum at a deeper level, over the anterior and lateral surface of 
aorta and around the branching of celiac trunk and superior mesenteric 
artery from the aorta. 
 
Celiac plexus is not a single ganglion. It is formed by a dense 
network of interconnecting nerve fibres between three independent ganglia 
namely celiac, superior mesenteric, and bilateral aorticorenal ganglia. 
Predominant fibres are the preganglionic sympathetic efferent nerve fibres.  
 These are derived from three splanchnic nerves namely the greater 
splanchnic (T5 through T9), the lesser splanchnic (T10 through T11), and 
the least splanchnic (T12) nerves. The vagus nerve through its posterior 
trunk contributes to preganglionic parasympathetic efferent fibres. 
                           COMPONENTS OF CELIAC PLEXUS 
  
Along with these splanchnic nerves, the visceral afferent fibres from 
pancreas, liver, biliary tract, gallbladder, spleen, adrenal glands, kidneys, 
mesentery, stomach, and the small and large bowels proximal to the 
transverse colon,  also course through the celiac plexus and finally 
terminate in the spinal cord. These visceral afferent fibres carry 
nociceptive stimuli from the distal esophagus, up to the proximal 
transverse colon i.e upper abdomen.  
CELIAC 
PLEXUS
CELIAC
GANGLIA
LEFT 
AORTICOREN
AL GANGLIA
SUPERIOR 
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 The celiac plexus thus represents the main centre for transmission of 
pain to the upper abdominal organs. Hence neurolysis of this relay centre is 
an effective method for manipulating pain that originates in these organs.  
 
The hypogastric plexus innervates the remainder of the large bowel 
i.e from the left colonic flexure to anus and the pelvic organs. Hence total 
visceral denervation is not a complication of celiac plexus neurolysis. 
The celiac plexus rests in the deep part of the retroperitoneal space 
and lies in the bed of fat anterior to the aorta, just below to the level of 
branching of the celiac artery from the aorta. 
Anteriorly it is related to the stomach and pancreas. Posteriorly, the 
diaphragmatic crus, separates the ganglia from the vertebral column. The 
  NERVE FIBRES IN THE CELIAC PLEXUS 
Preganglionic 
sympathetic 
efferents 
• Greater splanchnic (T5 through T9) 
• Lesser splanchnic (T10 through T11) 
• Least splanchnic (T12) nerves 
Preganglionic 
parasympathetic 
efferents 
• Posterior trunk of vagus nerve 
Visceral afferents • From pancreas, liver, biliary tract, 
gallbladder, spleen, adrenal glands, 
kidneys, mesentery, stomach, and the 
small and large bowels proximal to 
the transverse colon 
 
splanchnic nerves are situated posterior to the crus, in the retrocrural space. 
On the right posterolateral aspect, the ganglion is related to inferior vena 
cava. Further laterally are the bilateral kidneys.  
It is important to know the anatomical relations of the plexus as these 
are the structures that would be damaged during the procedure. The group 
of ganglia extend for several centimetres on the anterior and lateral aspect 
of aorta.  
 RELATIONS OF CELIAC PLEXUS 
Anteriorly • Stomach  
• Pancreas 
Posteriorly • Diaphragmatic crus 
• Splanchnic nerves 
• Vertebral column 
 
Zhang et al reported that the location of the celiac ganglia was found 
to be at the level of T12 or L1 in 94 % of cases. The right ganglion is 
slightly more cranial than the left. The left and the right celiac ganglia are 
positioned approximately 0.9 cm and 0.6 cm below the celiac artery. Size 
of the celiac ganglion ranges from 0.5 to 4.5 cm with a mean size of 2.7 
cm. The landmark for localisation of celiac ganglia is the celiac artery as 
its relationship with the ganglia is more consistent than the relationship of 
the vertebral column. 
MORPHOLOGICAL CHARACTERISTICS OF CELIAC PLEXUS 
Level • T 12 – L 1 
Size • Mean size 2.7 cm ( 0.5 – 4.5 cm ) 
Right ganglia • 0.6 cm below celiac artery 
Left ganglia • 0.9 cm below celiac artery 
 CT CROSS SECTIONAL ANATOMY  
On CT cross sectional imaging, the bilateral ganglia have a 
characteristic discoid or multilobulated configuration resembling the limbs 
of nearby adrenal gland. On axial CT images, the left ganglion is 
consistently located anteromedial to the left adrenal, between the adrenal 
gland and the diaphragmatic crus. The right ganglion is located 
consistently between the IVC and the right diaphragmatic crus, 
anteromedial to the right adrenal gland and posteromedial to the IVC. 
CT CHARACTERISTICS OF CELIAC PLEXUS 
Shape • Discoid or multilobulated 
configuration 
Level • At the level of pancreas 
Visualisation • Right less often seen than left 
Left ganglia 
location 
• Anteromedial to left adrenal, 
between  adrenal gland and the 
diaphragmatic crus 
Right ganglia 
location 
• Superior angle formed by the left 
renal vein entering into the IVC and 
is covered by the IVC 
NECT/ • Adrenals and celiac ganglia look 
 Portovenous 
phase 
similar 
Delayed 
images(10 min) 
• Persistent contrast enhancement of 
ganglia 
 
Zhang et al identified that the right celiac ganglion is commonly 
found at the superior angle formed by the left renal vein entering into the 
IVC and is covered by the IVC. The celiac ganglia are most commonly 
located at the level of the pancreas.  
Both the adrenal glands and the celiac plexus have similar 
attenuation values on unenhanced and portovenous phase CT image. The 
differentiating feature according to Wang et al lies in the persistent contrast 
enhancement of the ganglia on delayed images (10 minutes). 
The right ganglion is less often seen than the left because of the 
minimal space on the right side between the IVC and the right crus. 
 LOCATION OF CELIAC PLEXUS – NECT AXIAL SECTION
 
LOCATION OF CELIAC PLEXUS – CECT AXIAL SECTION 
 
RELATIONS OF CELIAC PLEXUS – NECT AXIAL SECTION 
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 MODALITIES OF  NEUROLYSIS 
        NEUROLYSIS UNDER CT GUIDANCE 
             Why CT guidance? Why not other imaging modalities 
  
The first ever blockade of splanchnic nerves in the management of 
upper abdominal pain was done by Kappis in 1919. He used palpable bony 
landmarks as the guide for his procedure. It was in the 1950’s that 
neurolysis under scopic guidance was done. This was followed by 
neurolysis under echographic guidance in 1970’s. Since then, the 
procedure and the technique of celiac plexus neurolysis has gone a long 
way. 
At present there are multiple modalities by which celiac plexus 
neurolysis can be achieved each having their own merits and demerits. The 
various available modalities include - Fluroscopic guidance, Ultrasound 
guidance, MDCT guidance, MRI guidance and Endoscopic Ultrasound 
guidance 
FLUROSCOPIC GUIDANCE   
Celiac plexus neurolysis under fluoroscopic guidance is a simple 
technique as does not need any expertise to operate the machine. Though 
the technique is simple and easy, there is no clear anatomical distinction 
 between the plexus and other intra abdominal structures which makes it 
tough.  
There is an overlap of abdominal structures like pancreas, great 
vessels, mass lesions and enlarged lymph nodes. This anatomical 
indistinction results in higher rate of complications like vascular or nerve 
injuries. The need for contrast is a disadvantage in patients with 
compromised renal status. 
FLUROSCOPIC GUIDANCE 
Advantage • Simple and easy 
Disadvantage • Anatomical indistinction 
• Need for contrast 
• Radiation 
• Higher incidence of complications 
 
ULTRASOUND GUIDANCE  
Ultrasound guided neurolysis is a very simple technique with low cost. 
Another advantage is that the aortic trunk, celiac trunk and SMA and other 
surrounding vessels are easily delineated in real time imaging. There is no 
need for radiation exposure. During injection of the neurolytic 
 pharmacological agent, its diffusion can be seen easily without the need for 
contrast obviating contrast related complications. 
The disadvantage is that the technique is operator dependent and it 
needs expertise for easy completion of the procedure. In addition the 
retroperitoneal organs are not clearly delineated which is a point of 
concern. 
ULTRASOUND GUIDANCE 
Advantage • Simple, cheap and easy 
• No risk of radiation 
• No need for contrast 
Disadvantage • Skilled personnel 
• Retroperitoneal dark areas 
 
MDCT GUIDANCE   
Celiac plexus neurolysis under CT guidance is the preferred 
modality at present. CT gives a clear picture of the anatomical relations of 
the intra abdominal structures including the retroperitoneal structures.  
Celiac artery, aorta, SMA, Renal vessels, adrenals, pancreas and 
kidneys are clearly delineated, thereby giving a clear picture of their 
 anatomical relations. Celiac plexus can be located on a CT which helps to 
plan the procedure. 
MDCT GUIDANCE 
Advantage • Anatomical distinction 
• High spatial and contrast resolution 
• Real time monitoring(CT fluro) 
• Pre and intra procedural planning 
Disadvantage • Radiation 
 
During procedure, with the help of CT, the point of needle entry, the 
trajectory and needle tip localisation can be achieved with ease obviating 
any unintended injury to nearby structures. Real time monitoring and 
visualisation of spread of neurolytic agent is achieved with CT 
fluoroscopy. 
The main disadvantage is radiation and its associated complications. 
 
MRI GUIDANCE  
Neurolysis under MRI guidance is more useful when there is a need 
for high soft tissue resolution. It also has the advantage of no radiation. 
 MRI GUIDANCE 
Advantage • Excellent soft tissue resolution 
• No risk of radiation 
• No need for contrast 
Disadvantage • High cost 
• Expert personnel 
• Availability 
 
exposure and its applicability in patients with compromised renal status as 
there is no need for contrast. However this technique is available only in 
specialized centres and it is expensive and requires expertise for a better 
outcome. 
 
ENDOSCOPIC ULTRASOUND GUIDANCE   
Celiac neurolysis under endoscopic ultrasound guidance is a better 
alternative to transabdominal ultrasound guided procedure.  
ENDOSCOPIC US GUIDANCE 
Advantage • Real time monitoring 
• Lesser complications 
 Disadvantage • Availability 
• Expert personnel 
• Invasive 
• Complications 
• Snow storm effect 
 
As it is anterior based, the neurological complications associated 
with posterior approach are obviated easily. It also helps in monitoring the 
spread of injected agent in real time. The disadvantage is that the technique 
is operator dependent and requires an expertise to locate the celiac ganglia 
especially after injection of lytic pharmacological agent due to ‘snowstorm 
effect’.  
To conclude, though there are multiple modalities for performing 
this procedure, CELIAC PLEXUS NEUROLYSIS UNDER CT 
GUIDANCE is the preferred method. However, depending on the patients 
anatomy, indications and availability, other modalities can also be 
performed.  
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 APPROACH TO THE PROCEDURE 
Why an anterior approach....? 
 
Just as there are many modalities for neurolysis, the approach to the 
procedure are also many. Each of these approaches evolved over time and 
each of them have their own indications, technique, advantages and 
disadvantages.  
The different approaches for celiac plexus neurolysis are: 
• Uni/Bilateral Posterior Paravertebral Antecrural Approach  
• Uni/Bilateral Anterior Paramedian Antecrural Approach 
• Uni/Bilateral Posterior Paravertebral Retrocrural Approach 
• Uni/Bilateral Posterior Transintervertebral Disk Approach 
• Left Posterior paravertebral Transaortic Approach 
• Uni/Bilateral/Multidirectional Direct Tumor Infiltration 
• Organ Traversal technique 
• Hydrodissection technique 
ANTECRURAL REGION  
As the name indicates it lies anterior to the aorta and crura on each 
side. The celiac plexus is located to this region. Hence this is the most 
commonly used site for injecting the pharmacological agent for neurolysis. 
 This region can be approached through various routes like bilateral 
posterior, bilateral anterior, transaortic, and transintervertebral disk 
approach.   
APPROACH TO ANTECRURAL REGION 
 
RETROCRURAL REGION  
As the name indicates, this region lies behind the crura and the aorta.  
APPROACH TO RETROCRURAL REGION 
 
BILATERAL POSTERIOR BILATERAL ANTERIOR
TRANSAORTIC TRANSINTERVERTEBR
AL DISK 
ANTECRURAL 
REGION
POSTERIOR
PARAVERTEBRAL
APPROACH
RETRO
CRURAL
REGION
 The splanchnic nerves are located to this region which are 
selectively blocked on infiltration of this region. This region is usually 
approached via the posterior paravertebral retrocrural approach. 
ANTE CRURAL AND RETRO CRURAL REGION ON CT 
 
 
BILATERAL VS UNILATERAL APPROACH   
Each of these approaches can be either unilateral or bilateral. But the 
spread of the pharmacological agent in the desired region i.e. antecrural or 
retrocrural is easily achievable through a bilateral approach. As the 
treatment success solely depends on the spread of the pharmacological 
agent, bilateral approach is preferred over the unilateral one.  
 
 BILATERAL VS UNILATERAL APPROACH 
 
To conclude, it is the bilateral approach that is preferred whenever it 
is possible. Unilateral approach is done only when bilateral approach 
cannot be done for some other reasons.   
 
 POSTERIOR PARAVERTEBRAL ANTECRURAL APPROACH  
This is the most commonly performed approach. Patients can be 
positioned prone or in lateral decubitus. The target region is the antecrural 
space which is approached by bilateral paravertebral route dorsally. From 
the point of entry, the needles  travel in the paravertebral space negotiating 
the vertebral transverse process and renal parenchyma until they reach the 
antecrural space between aorta (1- 2 cm anterior to aorta) and diaphragm 
posteriorly and pancreas anteriorly.  
CELIAC PLEXUS APPROACH
BILATERAL
Desirable
UNILATERAL
Less preferred
 The desired axial level is at a point between the celiac trunk and 
SMA branching from the aorta. Normally around 30 – 40 ml of the 
pharmacological agent is used. 
The advantage is that the dorsal surface which is the site of entry is 
more or less flat and does not show respiratory movements which makes 
the procedure simple. Most of the patients are comfortable in prone 
position, though they are more comfortable in supine position. Injury to the 
anterior abdominal viscera is less common as the needle falls short of these 
structures. 
The disadvantage is that the incidence of neurological 
complications, spinal cord trauma and renal injuries are more. It cannot be 
done in patients who cannot lie prone. Post procedure diaphragmatic 
irritation is also common. The neurological complications are either due to 
inadvertent spread of neurolytic agent in the retrocrural space or due to 
direct injury with the needle.  
 POSTERIOR PARAVERTEBRAL ANTECRURAL APPROACH 
Patient position • Prone or lateral decubitus 
Route • Posterior Bilateral paravertebral 
          Target region  • Antecrural space 
Volume of agent • 20 – 30 ml 
 Advantage • Comfortable 
• No visceral injury 
Disadvantage • Neurological complications 
• Diaphragmatic irritation 
• Spinal cord trauma 
 
B/L POSTERIOR PARAVERTEBRAL ANTECRURAL APPROACH  
TRAJECTORY 
        
  
 ANTERIOR PARAMEDIAN ANTECRURAL APPROACH  
In the past, celiac plexus neurolysis was done via anterior approach.  
This approach was first described by Wendling et al in 1918. As there were 
many complications associated with it, the procedure was abandoned. 
 However with the introduction of image guided technique, the 
complications have come down. 
In this procedure, patient lies supine. Patients feel more comfortable 
lying supine than prone. The approach is through the anterior abdominal 
wall on either side of the midline. From the point of entry, needle is 
directed towards the antecrural space (which is the target region) at a level 
between the celiac trunk and SMA.  
As the needle traverses from anterior abdominal wall to the 
antecrural space, it pierces the intra abdominal organs like stomach, liver, 
pancreas and bowel loops. This results in complications like gastric 
perforation, drug induced chemical peritonitis, fistulous tracts of pancreas, 
and subcapsular hematoma of the liver. However the incidence of these 
complications is very low. 
               B/L ANTERIOR PARAMEDIAN ANTECRURAL APPROACH    
                      TRAJECTORY 
 
 This approach is more suitable for post operative status patients who 
cannot lie prone. It also carries lesser risk for renal injury as it is away 
from the field. The neurological complications associated with posterior 
approach is also very less because this approach does not enter the 
retrocrural space. 
ANTERIOR PARAMEDIAN ANTECRURAL APPROACH 
Patient position • Supine 
Route • Anterior bilateral paramedian 
approach  
          Target region  • Antecrural space 
Volume of agent • 20 – 30 ml 
Advantage • Comfortable position 
• Used in post operative status 
• Less renal injury 
• Less neurological complications 
• Less diaphragmatic irritation 
Disadvantage • Perforation of viscera 
• Peritonitis 
• Liver hematoma 
• Vascular injuries 
 
 Thus, it is evident that a successful celiac plexus neurolysis can be 
done with any of these approaches. Though both these approaches have 
certain complications, they are less commonly seen. Hence the choice of 
approach is governed by various factors and it should be tailored for each 
individual.  
 
 POSTERIOR PARAVERTEBRAL RETROCRURAL APPROACH  
This approach is usually preferred when the anterior crural space is 
distorted for example pancreatic carcinoma or lymph node enlargement. As 
the antecrural space is obliterated the anterior approach cannot be 
performed. In such situations, this approach is preferred as the target for 
this is the retrocrural region.  
Injection of neurolytic agent into this space, preferentially blocks the 
splanchnic nerves which are the contents of this space. As it is a confined 
space it cannot take up large volumes of neurolytic agents. Hence generally 
about 5 – 10 ml is given. 
 As the antecrural space is not infiltrated with the agent, the outcome 
of this approach is less satisfactory.  
However, if this is performed in combination with infiltration of 
antecrural space, best possible results can be achieved.  As with any other 
 posterior approach, this is associated with neurological complications, 
spinal cord injury and diaphragmatic irritation. 
POSTERIOR PARAVERTEBRAL RETROCRURAL APPROACH 
Patient position • Prone 
Route • Posterior bilateral paravertebral 
           Target region  • Retrocrural space 
Volume of agent • 5 – 10 ml 
Advantage • Preferrential splanchnic nerves 
blockade 
• In combination with antecrural space 
block, maximum results achieved 
Disadvantage • Neurological complications 
• Diaphragmatic irritation 
• Spinal cord trauma 
TRAJECTORY 
 
 POSTERIOR TRANSINTERVERTEBRAL DISK APPROACH  
In this approach, the needles are passed through the intervertebral 
disc space instead of the paravertebral route. This approach is preferred 
only when the paravertebral approach cannot be performed for any 
reasons.    
Patients are positioned prone. Usually the intervertebral disc spaces  
between T12 and L2 are used. As the needle passes through disc space, 
injuries to abdominal viscera is less likely.  
POSTERIOR TRANSINTERVERTEBRAL DISK APPROACH 
Position • Prone 
Route • Posterior bilateral trans intervertebral 
disc 
Target region • Antecrural space 
Volume of agent • 20 – 30 ml 
Advantage • Helpful when paravertebral route is not 
accessible for other reasons 
• Less visceral injury 
Disadvantage • Discitis 
• Disc herniation 
• Spinal cord injury 
 The target area is the antecrural space. Positioning of the needle tip 
within this space is confirmed by, a give away feel, due to loss of 
resistance, on piercing the anterior longitudinal ligament. 
As the needle passes through the intervertebral disc space this 
approach is prone for complications like Disc inflammation, disc 
disruption, herniation and spinal cord injury. Because of these 
complications, this is never a first choice approach. 
POSTERIOR TRANSINTERVERTEBRAL DISK APPROACH 
TRAJECTORY 
 
 
Lt POSTERIOR PARAVERTEBRAL TRANSAORTIC APPROACH 
In this approach, needle is passed through the walls of the aorta. Patients 
are positioned prone. A single needle is used which is passed in the left 
paravertebral region towards the direction of aorta.  
 On reaching the aorta, both the anterior and posterior walls are 
pierced to reach the antecrural space. On reaching this space, the procedure 
is the same as with any other approach.  
There are no specific indications for this approach. The only 
advantage of this approach is that a single needle is sufficient in this. As 
the needle tip reaches the midpoint of the antecrural space, there will be 
free spread of drug on both sides immediately after injection. 
It is important to have a complete pre procedure evaluation of the 
patient for any aneurysms or dissection or abnormal branching of aorta and 
for any other intraabdominal pathologies which may affect the outcome.  
However this approach is associated with risk of massive hemorrhage 
which can be life threatening. 
LEFT POSTERIOR PARAVERTEBRAL TRANSAORTIC APPROACH 
Position • Prone 
Approach • Left posterior paravertebral 
transaortic 
Target • Antecrural space 
Volume of agent • 15 – 25 ml 
Advantage • Single needle alone required 
 • Less spinal cord injury 
Disadvantage • Massive bleeding 
 
LEFT POSTERIOR PARAVERTEBRAL TRANSAORTIC APPROACH  
TRAJECTORY 
 
 DIRECT INFILTRATION OF THE TUMOR    
This technique is done for patients whose antecrural space is 
completely obliterated by a tumor mass. As there is no space for 
infiltrating the drug, it is infiltrated into the tissue itself which occupies the 
space. This destroys the tumor to some extent and the infiltrated celiac 
ganglion as well thereby resulting in the desired effect. 
DIRECT INFILTRATION OF THE TUMOR 
Position Prone 
Approach Multidirectional anterior 
 transabdominal 
Target Tumor mass in antecrural space 
Volume Larger volumes required 
Indication When entire antecrural space is 
infiltrated by a tumor mass 
Disadvantage Poor pain relief 
 
It can be done with any number of needles, the requirement being 
that the maximum area of the tumor mass should be covered. In contrary to 
other techniques, as the drug is infiltrated into tissue instead of a free 
space, there will be high resistance while delivering the drug. 
DIRECT INFILTRATION OF THE TUMOR - TRAJECTORY 
 
 
 ORGAN TRAVERSAL TECHNIQUE  
This technique is commonly used in an anterior approach as there 
are too many intraabdominal structures between the anterior abdominal 
wall and the celiac plexus. In this technique, as the name indicates, the 
abdominal viscera along the trajectory of the needle are traversed to reach 
the celiac ganglion.  
 
However care should be taken not to injure the structures like blood 
vessels, bile duct, biliary radicles, porta hepatis, renal pelvis and fecal 
filled colonic loops. It is important to rule out any coagulopathies before 
this procedure. 
Some of the complications associated with this technique are 
pancreatitis (while traversing pancreas), hematoma (Liver) and urinoma 
(Kidney). Whatever be the approach, there should be sufficient volume and 
spread of the neurolytic agent for successful treatment. 
  
 
 
NEUROLYTICAGENT 
– ETHANOL VS PHENOL 
 
 
 
 NEUROLYTIC AGENT 
Ethanol Vs Phenol 
 
Neurolysis is a procedure in which a neurolytic agent is used to 
destroy the nerves. This can be temporary or permanent. A temporary 
disruption of neuronal function is called a block, whereas permanent 
disruption is termed neurolysis. 
Neuronal block, which is temporary, can be achieved with 
corticosteroids or small doses of local anaesthetics.  
Neurolysis, which is permanent requires the infiltration of a 
neurolytic agent which completely destroys the nerves. Most commonly 
used neurolytic agents are absolute alcohol (Ethanol) and phenol. 
Ethanol is the most commonly used neurolytic agent worldwide. The 
preferred concentration of ethanol is 100%, which is absolute alcohol. 
However in practice, it is difficult to get it at this concentration. Even if it 
is obtained, the concentration decreases with time on storage. 
However it has been found that for proper neurolysis a concentration 
between 50 % to 100 % is sufficient. Another important factor which 
governs the outcome of the procedure is the diffusion of the neurolytic 
agent at the desired site. 
 Ethanol has got a faster onset of action. It was reported for 
neurolysis in 1931 by Dogliotti. It causes neurolysis by precipitation of 
proteins within the nerves. Once the lipoproteins and mucoproteins are 
precipitated, the cholesterol, glycosaminoglycans, phospholipid and 
cerebrosides are extracted from the nerves resulting in neurolysis.  
However it should be noted that the basal lamina of Schwann cell 
sheath remains intact. This intact basal lamina can proliferate (Schwann 
cell proliferation) which acts as a framework for regeneration of nerve 
fibres. This is the reason why neurolysis is ineffective after 6 – 8 months. 
Ethanol is more effective at ganglion cell level rather than preganglionic or 
postganglionic fibres.  
Ethanol is a low viscous liquid which enables early diffuse diffusion 
in the space available. Because of its low viscocity it can be easily mixed 
with local anaesthetics for intraoperative pain management and with 
contrast for identifying its spread. However there will be transient pain 
while injecting ethanol due to its irritant nature. More than 90% ethanol 
that is injected is completely oxidized in the liver by alcohol 
dehydrogenase. 
Phenol is less commonly used. It is a highly viscous liquid used in 
concentrations of 3 % to 20 %. It has a local anaesthetic effect preventing 
any pain during injection.  
 The high viscocity prevents it from being mixed with local 
anaesthetics and contrast. It spreads slowly, again because of the viscocity 
with a slow onset of action. When administered, phenol causes coagulation 
and necrosis of the proteins within the nerves thereby destroying it. 
FACTORS ETHANOL PHENOL 
Viscocity Low High 
Concentration 50 to 100 % 3 to 20 % 
Preference Preferred Less preferred 
Onset Immediate Delayed 
Mechanism Precipitation Coagulation 
Diffusion Spreads easily Spreads sparsely 
Injection site pain Present Absent 
Outcome Excellent Moderate 
 
Thus ethanol is the preferred neurolytic agent at a concentration of 
50 – 100 %. It is generally used as a mixture with local anesthetic (for 
anaesthetic effect) and contrast (for visualizing spread). 
 
 
 
 So far we have seen, what pain meant to our ancestors and what 
it means to us now and the transformation from older beliefs and ideas 
to newer concepts under the heading of JOURNEY OF PAIN – 
HISTORY REVISITED. 
 
 Then we discussed each and every component of the topic 
namely “CT GUIDED CELIAC PLEXUS NEUROLYSIS THROUGH 
ANTERIOR APPROACH “  in the form of RATIONALE behind the 
neurolysis, ANATOMY and PHYSIOLOGY of celiac plexus, various 
available MODALITIES and why CT GUIDANCE was preferred, 
VARIOUS APPROACHES to reach the target  area and why 
ANTERIOR APPROACH was preferred and a quick analysis of the 
various NEUROLYTICS and the preferred neurolytic agent. 
 
With this knowledge, let us now focus on cancer pain in 
particular and its implications, assessment of pain, various treatment 
options for treatment of cancer pain, indications and contraindications 
for the procedure, patient preparation and the steps involved in the 
procedure, the results and the analysis of the outcome. 
 
  
 
 
PATHOPHYSIOLOGY OF PAIN 
 
 
 
 
 PATHOPHYSIOLOGY OF PAIN 
 
CHRONIC PAIN ETIOLOGY IN CANCER 
Chronic pain in malignancies may be due to one of the following 
mechanisms. 
Pain directly due to cancer –  
• Infiltration or compression of nerve tissue due to tumor 
 Peripheral nerves 
 Plexus 
• Infiltration of bone by tumor 
• Obstruction of hollow viscus 
• Obstruction of arteries and veins by tumor 
• Stretching of fascia / periosteum 
• Inflammation due to necrosis and infection 
Pain associated with cancer therapy –  
• Following surgery 
 Acute post operative pain 
 Nerve trauma 
 Entrapment of nerves in scar tissue 
 • Following radiotherapy 
 Acute lesions of nerves or plexus 
 Radiation fibrosis of nerves or plexus 
 Myelopathy of spinal cord 
• Following chemotherapy / steroids 
 Peripheral neuropathy 
 Aseptic necrosis of bone 
 
METHODS OF TREATING CANCER PAIN   
Broadly, the treatment of cancer pain can be divided into 
 Pharmacological methods 
 Palliative radiotherapy 
 Neurolytic / Neurosurgical procedures 
The pharmacological methods of treatment of cancer pain have been 
briefly dealt with along with the JOURNEY OF PAIN – HISTORY 
REVISITED. In short, it is the opiate group of drugs that form the main 
stay of treatment of cancer pain. However, with time, with progression of 
the disease, it becomes difficult to strike a balance between drug dose, side 
effects and pain alleviation. 
 Palliative radiotherapy is done for terminally ill patients for whom 
nothing else can be done.  
 
NEUROLYTIC / NEUROSURGICAL PROCEDURES 
There are various number of neurolytic / neurosurgical procedures 
for relieving chronic intractable pain such as –  
 Nerve section 
 Sympathectomy 
 Myelotomy to section spinothalamic fibres in anterior white commissure 
 Posterior rhizotomy 
 Anterolateral cordotomy 
 Medullary tractotomy 
 Mesencephalic tractotomy 
 Thalamotomy 
 Gyrectomy 
 Prefrontal lobotomy 
 
The possibility of controlling otherwise intractable pain by the 
relatively brief application of a local anesthetic or neurolytis agent makes 
neural blockade an attractive approach in selected patients. Published 
 estimates of the percentage of all patients with cancer pain for whom, 
nerve 
 
NEUROSURGICAL PROCEDURES 
1- Nerve section ; 2– Sympathectomy ; 3– Myelotomy to section 
spinothalamic fibres in anterior white commissure ; 4– Posterior 
rhizotomy ; 5– Anterolateral cordotomy ; 6– Medullary tractotomy ; 7– 
Mesencephalic tractotomy ; 8– Thalamotomy ; 9– Cingulate gyrectomy ; 
10– Prefrontal lobotomy 
 block procedures may appropriately be considered vary greatly. Allowing 
for vagueness in methods of arriving at published estimates, lack of 
uniformity in clinical conditions treated by neural blockade, and in 
reported clinical outcomes, it still appears that some 50 to 80 % of patients 
who receive nerve blocks for cancer pain may benefit. 
Neurolytic sympathetic blockade is useful to relieve pain in the arm, 
head and neck (Stellate ganglion), or leg (Lumbar plexus block), as wel to 
interrupt the visceral afferent pain pathways mediating pain in the pancreas 
and other upper abdominal organs (Celiac plexus block)or in the pelvis 
(Hypogastric block / Ganglion of impar block). 
Because of the appeal of nerve blocks for use in intractable pain and 
their potential for harm as well as benefit, the following guidelines have to 
be observed –  
o Assess thoroughly each patients pain mechanism, in order to apply the 
most appropriate block via appropriate approach 
o Screen patients thoroughly, according to coexistent medical conditions and 
the ability to understand the risks of the proposed procedure. 
o Consider a block, only if the person panning to do is experienced and 
skillfull. 
o Use radiographic control because both ease and safety depend on the 
precise identification of landmarks. 
  
 
 
 
ASSESSMENT OF PAIN 
 
 
 
 
 
 ASSESSMENT OF PAIN 
 
Assessment of pain pre procedure and post procedure provides some 
indication of sympathetic block, pain relief can be reported almost 
immediately after the procedure or can be delayed for several hours in 
some patients. A large number of scales and questionnaires have been used 
to measure pain. Three factors are important in assessment of pain are :  
o Sensory intensity of pain 
o Associated positive or negative mood 
o Pain related interference with activities 
 
SENSORY INTENSITY OF PAIN   
The commonly used measures of pain intensity are  
 Category scales 
 Visual Analog scales 
 McGill’s pain questionnaire 
 Gracely’s verbal descriptor scale 
 
 VISUAL ANALOG SCALE ( VAS )   
The Visual Analog Scale ( VAS ), provides a simple efficient and 
minimally intrusive measure of pain intensity, that has been used widely in 
clinical and research settings, where a quick index of pain is required for 
which a numerical value can be assigned. The VAS consists of a 10 cm 
horizontal or aq vertical line with the two end points labelled “no pain“ and 
“worst pain ever” (or a similar verbal descriptor representing the upper 
pole).  
The patient is expected to mark on the 10 cm line, a point, that 
corresponds to the level of pain intensity, he/she currently feels. The 
distance in centimetres from the lower end of the scale and the patient’s 
mark is used as a numerical index of the severity of pain. 
The VAS is sensitive to pharmacologic and non pharmacologic 
procedures that alter the experience of pain and correlates highly with pain 
measured on verbal and numerical rating scales. Instruction to patients to 
rate the amount of percentage of pain relief using VAS (eg.. following 
administration of a treatment designed to reduce pain) may introduce 
necessary bias (eg .. expectancy for change and relies on no memory), 
which reduces the validity of the measure. It has been suggested, therefore 
that a more appropriate measures of change may be obtained by having 
 patients rate the absolute pain at different points in time (eg.. pre procedure 
and post procedure at different points of time). 
A major advantage of VAS as a measure of pain intensity is its ratio 
scale properties. In contrast to many other pain measurement tools, 
equality or ratios is implied, making it appropriate to speak meaningfully 
about percentage difference between VAS measurements obtained either at 
multiple points in time from independent samples of subjects.  
Thus ratio statements, may be made, that described pain in one 
group of patients as being several times that of another or as being reduced 
by a certain percentage. The ratio scale property of the VAS also means 
that the measurements are suitable for assessment using parametric 
statistics and are means to paramedic inferential statistical procedures. 
 Other advantages of VAS include its ease and brevity of scoring, 
minimal intrusiveness and its conceptual simplicity (provided adequately 
clear instructions are given to the patient). 
The major disadvantage of VAS is that the assumption that pain s a 
unidimensional experience. Each pain has unique qualities. To describe 
pain solely in terms of intensity is inadequate. 
 
  
 
 
 
 
PAIN ASSESSMENT METHODS 
 
 
 
 
 PAIN ASSESSMENT METHODS 
VISUAL ANALOG SCALE
0      1         2         3         4         5         6         7         8         9         10  
LOWEST 
POSSIBLE PAIN 
HIGHEST
POSSIBLE PAIN 
 
 
GRACELEYS VERBAL  DESCRIPTOR SCALE
Extremely intense
Very intense
Intense
Strong/ Slightly intense
Moderate / Barely strong
Mild
Very mild
Weak
Very weak 
Faint
No pain sensation
 
 CATEGORY SCALES   
The oldest of the standard measures is four point pain intensity 
category scale. Although this measure is still the most widely used scale, it 
has been criticized on several counts. Patients have indicated that a four 
point pain intensity scale does not have enough levels to allow them to 
accurately describe their pain levels 
Pain intensity category scale (4 points)  
 Severe   - 3  
 Moderate   - 2 
 Mild   - 1  
 None    - 0 
Pain relief category scale (5 points)   
• Complete   - 4 
• Lots   - 3 
• Moderate   - 2 
• Slight    - 1 
• None   - 0 
Compared to the pain intensity category scale, relief category scales 
have been reported to be more sensitive to small reductions in pain: the 
 same advantage has been suggested for VAS relief scale over VAS pain 
scales. 
The disadvantages of the McGill pain questionnaire are that it takes 
five minutes to complete, compared to seconds for VAS and category 
scales, requires a rich vocabulary and confuses some patients 
 
GRACELEY’S VERBAL DESCRIPTOR SCALE   
This also uses verbal descriptors but they are fewer than in McGill 
questionnaire. It has a list of thirteen pain intensity descriptors. Each word 
has a numerical equivalent established by cross modality matching 
methods. 
Both the VAS and the Graceley’s 13 point VDS were used because of 
the inherent simplicity and ease of administering the test. 
 
   
 
 
 
  
 
 
INDICATIONS 
 
 
 
 
 INDICATIONS 
 
The indications in general for a celiac plexus neurolysis are : 
 
• Patients with persistent and intractable upper abdominal pain due to 
malignancies / Chronic Pancreatitis of inoperable status 
 
• Patients with severe nausea and hyperemesis due to Pancreatic cancer  
 
• In visceral neuropathy in patients with diabetes, Inflammatory bowel 
disease (Crohn’s disease) and sclerosing cholangitis of AIDS. 
 
 
In this study, the procedure has been restricted to intractable upper 
abdominal pain due to malignancies or chronic pancreatitis only.  
Patients with nausea and hyperemesis due to pancreatic cancer were not 
included in this study, as this study is for evaluating pain relief by this 
procedure. 
  
 
 
CONTRAINDICATIONS 
 
 
 
 
 CONTRAINDICATIONS 
 
There are no absolute contraindications for this procedure. All are 
relative contraindications. They are as follows:  
• Coagulopathies  
• Hypovolemic status 
• Ascites 
• Abdominal aorta aneurysm 
• Intraabdominal sepsis 
• Bowel obstruction / Tumors  
• Gastric outlet obstruction causing stomach distension 
 
Apart from these general contraindications, there are certain 
contraindications due to pathologies indigenous to each of the approaches. 
For example, Discitis and Ankylosing spondylitis are contraindications for 
an intervertebral disc approach; intraarterial thrombus is a contraindication 
for transarterial approach. 
  
 
 
PATIENT PREPARATION 
 
 
 
 
 PATIENT PREPARATION 
 
Patient preparation is very important for a successful outcome. It 
involves the following: 
 
Patient selection – It is important to select patients properly, as the 
procedure can help, only in conditions where the pain is mediated through 
celiac plexus. 
Ultrasonogram – It is important to do get an ultrasonogram of the 
abdomen done so as to rule out any pathologies that can affect the 
procedure. This can be done on an out patient basis thereby helping in 
patient selection.  
Admission - It is important to have the patients in admission for pre and 
post procedure care. 
Coagulation profile – Patients coagulation profile (BT, CT, PT and INR) 
should be assessed carefully as with any other intervention procedure. 
Hydration status – It is important to assess blood pressure and hydration 
status as this procedure can lead to hypotension. Hydration with 
intravenous fluids is done in all patients especially if hypovolemic. 
 Patient Education – It should be ensured that the patients are explained 
clearly about the indications, contraindications, preparation, procedure 
techniques, complications, outcome both in benefits and failure aspect, 
post procedure care and more importantly pain assessment using VAS. 
Vitals and blood parameters – Regular monitoring of vitals with 
evaluation of  ECG, Complete blood count, Renal function tests, Liver 
function tests and allergic status are done. 
Fasting and medications – Patients are advised to fast for 8 hours before 
procedure. It is advised to change to heparin if on any oral anticoagulants, 
which should be withheld on the day of procedure along with 
hypoglycaemic agents. The rest of the medications can be taken as usual. 
Consent – As with any other procedure, a written consent is obtained from 
the patient as well as the guardian. 
Intravenous access – Patients should have an intravenous access with an 
18 G venflon. 
Abdomen preparation – Patients abdomen should be prepared. 
X – ray spine – It is essential if an intervertebral disc approach is planned 
Doppler and CT angiogram of abdomen – It is done before a transarterial 
approach. 
  
 
 
PROCEDURE REQUISITES 
 
 
 
 
 PROCEDURE REQUISITES 
 
• It is made sure that the CT is dedicated for the procedure until it is 
completed 
 
• Boyle’s apparatus in complete shape with adequate oxygen supply is 
ensured 
 
• Resuscitative measures are kept ready: 
 Laryngoscope with blades 
 Endotracheal tubes of appropriate sizes with connectors 
 Emergency drugs – Inj.Atropine, Inj.Adrenaline, Inj.Ephedrine, 
Inj.Hydrocortisone, Inj.Diazepam, Inj.Avil and Intravenous fluids. 
 
• Procedure tray – It consists of Surface marker, Povidone iodine, sterile 
gauze, sponge holding forceps, drape sheets, 2% lignocaine without 
preservative, 11 surgical blade, 20 G Chiba or Spinal needle, Contrast and 
neurolytic agent and adhesives.  
 
 
  
 
 
DESCRIPTION OF THE PROCEDURE 
 
 
 
 
 DESCRIPTION OF THE PROCEDURE 
The procedure involves the following steps: 
• Pre procedure VAS is obtained. 
• Premedication with Inj.Pentazocine and Inj.Atropine  
• Patient is positioned supine.  
• A surface marker is placed over the patient abdomen at T12 to L2 level.  
• A NECT abdomen is performed.  
• Celiac artery and celiac plexus are localized and the best axial slice 
selected. 
• The puncture sites are then selected. The surface marker gives the long 
axis and the CT machine lazer beam of the axial slice gives the horizontal 
axis.  
• From the point of entry, the trajectory is planned (which is the third axis) 
on the console and depth measured. 
• Patient abdomen is painted with povidone iodine and draped. 
• Skin and the anterior abdominal wall infiltrated with 2% lignocaine on 
both sides. 
• Puncture site incision is made with 11 surgical blade. 
• 20G Chiba or Spinal needle is passed from the puncture site along the 
trajectory up to the target site, the antecrural space, bilaterally. 
 • The needle tip is first located with the tip artefact. A negative suction helps 
to rule out intra arterial placement of needle tip.  
• Then a mixture of 3 ml of 2% lignocaine with 1ml of contrast is injected 
on each side. In this mixture, lignocaine serves two purposes. First, it 
assesses the needle tip by evaluating the spread. Second, the injected 
lignocaine, if produces mild reduction in pain, warrants a successful 
outcome.  
• Contrast is added to the mixture, to facilitate the spread of the injected 
liquid in the target space. As the HU of ethyl alcohol is -210 units, like that 
of surrounding Fat, its spread cannot be assessed, if it is injected 
separately. 
COMPARISON OF HU OF ALCOHOL AND NS 
CORONAL VIEW 
 
  
AXIAL VIEW 
 
• Once this is confirmed, a mixture of 15 ml of neurolytic agent (Absolute 
alcohol) and 5 ml of 2% lignocaine is injected on each side. It is important 
to rule out intra arterial injection by applying negative suction. As the HU 
of alcohol is  - 210  units, its spread can be appreciated only by means of 
hydrodissection. Lignocaine is added to alleviate any transient pain, 
associated with alcohol injection and for immediate neurolytic effect. 
• The needles are then removed (Before withdrawing, the needles are 
flushed with saline to prevent spillage of alcohol in the trajectory which is 
painful) and hemostasis secured with manual pressure if needed and 
adhesives applied. 
• Immediate post procedure pain evaluation with VAS is obtained on the 
table. 
 
  
 
 
POST PROCEDURE CARE 
 
 
 
 
 POST PROCEDURE CARE 
 
• Patient is shifted to the ward and advised strict bed rest for 12 hours. 
 
• Regular monitoring of vitals is done. 
 
• Proper hydration with intravenous fluids. 
 
• Patient can resume normal diet immediately after the procedure. 
 
• A complete neurological examination done at 24 hours post procedure. 
 
• A post procedure pain score – VAS score is obtained at 24 hours. 
 
• Follow up VAS score obtained at 1 week, 1 month and 2 months. 
 
 
 
 
  
 
 
COMPLICATIONS 
 
 
 
 
 COMPLICATIONS 
   
There are no major complications associated with the procedure 
provided it is done with proper care. The associated complications are: 
 
• Hypotension – This is the commonest complication. This is due to loss of 
sympathetic tone, due to lysis of the sympathetic ganglion. Adequate 
hydration before and after the procedure prevents this complication. 
 
• Back pain – This is primarily due to lysis of sensory nerves of the celiac 
plexus. Usually settles within 72 hours. 
 
 
• Shoulder pain – This is due to diaphragmatic irritation, which settles in 72 
hours. 
 
• Diarrhoea – This is due to unopposed parasympathetic activity after 
sympathetic neurolysis. It is self limiting. 
 
 
 • Local hematoma 
 
• Discitis, lower limb weakness, sphincter dysfunction of bowel and 
bladder and spinal ischemia due to spinal artery infarct are rare but 
possible severe complications. These can be prevented with proper 
technique of the procedure. 
 
 
• No pain relief – A proper outcome depends mainly on the amount and the 
spread of neurolytic agent in the ante crural space. In properly selected 
patients, if the volume and spread are satisfactory, a good response is 
warranted. 
 
 
   
 
 
 
 
 
  
 
 
MATERIALS AND METHODS 
 
 
 
 
 MATERIALS AND METHODS 
  
The study is a prospective study, which was done in the BARNARD 
INSTITUTE OF RADIOLOGY, RAJIV GANDHI GOVERNMENT 
GENERAL HOSPITAL, MADRAS  MEDICAL COLLEGE, CHENNAI, 
from JUNE 2014 TO SEPTEMBER 2014, after obtaining due permission 
and clearance from THE ETHICAL COMMITTEE. 
 The study was done after obtaining permission from THE 
DEPARTMENT OF SURGICAL GASTROENTEROLOGY and THE 
PAIN CLINIC attached to THE INSTITUTE OF ANESTHESIOLOGY 
AND CRITICAL CARE, from where the patients were referred for the 
procedure. 
 Procedure done with 4 slice TOSHIBA CT scanner - ASTEION, located 
at 203, Tower II, RGGGH and MMC. Patients were carefully selected 
using inclusion and exclusion criteria. Patients pre operative instructions 
verified and proper consent obtained after educating them about the 
procedure. Pre operative assessment of pain done using VAS.  
 Patient in supine position, through bilateral paramedian anterior 
approach, the procedure is carried out as detailed earlier. Immediate post 
 procedure pain assessment is done on the table. Patient sent to ward with 
proper  
 
ASTEION – TOSHIBA 4 SLICE CT SCANNER 
 
post procedure instructions as detailed. A complete neurological 
examination is done at 24 hours post procedure.  
 
 
 
 
  
 
 
REPRESENTATION CASES 
 
 
 
 
 REPRESENTATION CASES 
CASE 1 
 
 
Scout with surface marker 
 
Spread of contrast in the antecrural space post procedure 
 CASE 2 
 
 
 Surface marker placement for planning the trajectory 
 
 
Spread of neurolytic in the antecrural space post procedure 
 CASE 3 
 
 
Needle trajectory- antecrural space 
 
 
Spread of contrast/ Lignocaine mixture 
 CASE 4 
 
 
Needle placement in antecrural space 
 
 
Spread of neurolytic agent post procedure 
  
 
 
EVALUATION 
 
 
 
 
 EVALUATION 
 
As the aim of this procedure is to alleviate pain, assessment of pain 
intensity is primarily done during evaluation. This is done using VISUAL 
ANALOG SCALE (VAS). 
Pain intensity assessment is done at different points of time. The 
first evaluation is done pre procedure. This is followed by immediate post 
procedure assessment on the table, at 24 hours, at one week, at one month 
and at 2 months time.  
Patients were also evaluated for complications. Hypotension was the 
commonest of them seen in 18 patients (9 males and 9 females). All these 
patients settled with intravenous fluids. Back pain was the second most 
common complication, seen in 14 patients (6 males and 8 females). 
Shoulder pain was seen in 12 patients (6 males and 6 females).  
Diarrhoea, hematoma, Discitis, lower limb weakness, sphincter 
dysfunction of bowel and bladder and spinal ischemia were not seen as 
complications in this study, involving 30 patients. 
Failure to achieve relief was also not reported in this study 
indicating a favourable outcome. 
  
 
 
STATISTICAL ANALYSIS 
 
 
 
 
 STATISTICAL ANALYSIS 
 
AGE GROUP –  
  
Eligible patients were selected using the inclusion and exclusion 
criteria. In total, 30 patients were included in the study. Of these 30 
patients, 14 belonged to the age group of 20 – 40 years, 16 to 40 – 60 years 
and no patients were in the age group below 20 or above 60 years. 
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GENDER CHART – 
 
 Of the 30 patients, 17 were males and 13 females. Of 17 males, 9 were of 
20 – 40 years and 8 were of 40 – 60 years. Of the 13 females, 5 were of 20 
– 40 years and 8 were of 40 – 60 years. 
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 DISEASE CHART –  
 The 30 patients included in the study had four types of diseases namely 
CHRONIC PANCREATITIS (TYPE I), PANCREATIC 
CARCINOMA(TYPE II), PERIAMPULLARY CARCINOMA(TYPE III) and 
GASTRIC CARCINOMA(TYPE IV).  There were 15, 7, 4 and 4 patients in 
each of these disease conditions respectively. There were 10 males and 5 
females in TYPE I disease, 3 males and 4 females in TYPE II disease, 2 
males and 2 females in TYPE III disease, 2 males and 2 females in TYPE 
IV disease. 
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ANALGESIC DRUGS – OPIATES –  
 
All the 30 patients were on high dose opiates requiring dose 
escalation every now and then due to poor control of pain. However, none 
of these patients had any side effects at the time of the study. Patients were 
carefully selected at an early stage of the disease as it is well known that, 
earlier the procedure better is the outcome. 
 The dosage aspect of the drugs, before and after the procedure was not 
taken into account for the study (Though it is one way of assessing 
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 treatment success) because the type of analgesic treatment was partly 
governed by availability of drugs at our institution.  
 
PAIN INTENSITY STATISTICS –  
  
 The intensity of pain was assessed using VAS. This assessment was done 
at different points in time namely  
• Preprocedure       –  PP VAS 1 
• Immediate postprocedure   –  VAS 2 
• At 24 hours      –  VAS 3 
• At one week       – VAS 4 
• At one month       –  VAS 5 
• At 2 months      –  VAS 6 
 
Mean PP VAS score was 8.67 ± 0.322 with a standard deviation of 
0.884. Mean of VAS 2 was 3.87 ± 0.23 with a standard deviation of 0.629. 
Mean of VAS 3 was 2.63 ± 0.21 with a standard deviation of 0.556. Mean 
of VAS 4, VAS 5 and VAS 6 were 1.80 ± 0.20 with a standard deviation of 
0.551. 
 This indicates that there is significant difference between means of 
PP VAS 1 and VAS 2, (from 8.67 to 3.87) with a percentage reduction of 
1- 3.87/8.67 = 55%, indicating good pain relief. Pain intensity further 
decreases from 3.87 to 2.63, at 24 hours (VAS 3), percentage reduction 
of 1-2.63/3.87 = 32%, after the procedure. There is further minimal pain 
relief from 2.63 to 1.8 at one week (VAS 4), percentage reduction 0f 1-
1.8/2.63 = 31%. Further follow up at one and two months showed no 
pain relief.  
 
 
 
95% Confidence Interval for 
Mean 
VAS N Mean Std. Deviation Std. Error Lower Bound Upper Bound 
1 30 8.67 .884 .161 8.34 9.00 
2 30 3.87 .629 .115 3.63 4.10 
3 30 2.63 .556 .102 2.43 2.84 
4 30 1.80 .551 .101 1.59 2.01 
5 30 1.80 .551 .101 1.59 2.01 
6 30 1.80 .551 .101 1.59 2.01 
       
 
        
  The minimum and maximum VAS scores were 7 and 10, 3 and 5, 2 and 4 
for PP VAS 1, VAS 2 and VAS 3. For the later VAS, it was 1 and 3 for all 
assessments. 
 
MEAN PAIN INTENSITY Vs VAS(1-6) 
 
 
The percentage reduction between PP VAS and VAS 6 is 1-
1.8/8.67 = 79%. 
The percentage reduction of pain is calculated by the formula 
                         1 -  Later value/Former value 
 
0
1
2
3
4
5
6
7
8
9
10
PP VAS 1 VAS 2 VAS 3 VAS 4 VAS 5 VAS 6
M
E
A
N
 V
A
S
 S
C
O
R
E
MEAN VAS SCORE
  SCORE 
VAS Minimum Maximum 
1 7 10 
2 3 5 
3 2 4 
4 1 3 
5 1 3 
6 1 3 
Total 1 10 
 
 The data does not show much of deviation from the mean, i.e it is non 
skewed data. Since the same variable is assessed at different points in time, 
ie repeated measurements of same variable, ANOVA is used for statistical 
analysis.  
 ANOVA stands for Analysis of Variance, which is an extension of Paired 
T-test. 
  The ANOVA for between groups gives a F value of 544.062 
which is statistically significant at 0.000 level. 
 
 
 ANOVA 
 
VAS Sum of 
Squares df 
Mean 
Square F Sig. 
Between  Groups 1086.561 5 217.312     544.062 .000
Within  Groups 69.500 174 .399 
  
Total 1156.061 179 
   
   
   
For within groups analysis, POST HOCS test is done for MULTIPLE 
COMPARISONS. 
   
The mean difference in pain intensity between PP VAS 1 and other 
post procedure VAS (2 to 6) shows significant alleviation of pain, which 
were statistically significant at 0.05 level.  
The mean difference in pain intensity between VAS 2 and VAS 3 
and that between VAS 3 and VAS 4 were also statistically significant at 
0.05 level. However, there was no statistically significant difference 
between VAS 4, VAS 5 and VAS 6. 
 
 
 POST HOCS TEST 
MULTIPLE COMPARISONS 
 
(I) 
VAS 
(J)  
VAS 
Mean 
Difference (I-J) 
Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
1 2 4.800* .163 .000 4.48 5.12 
 
3 6.033* .163 .000 5.71 6.36 
 
4 6.867* .163 .000 6.54 7.19 
 
5 6.867* .163 .000 6.54 7.19 
 
6 6.867* .163 .000 6.54 7.19 
2 1 -4.800* .163 .000 -5.12 -4.48 
 
3 1.233* .163 .000 .91 1.56 
 
4 2.067* .163 .000 1.74 2.39 
 
5 2.067* .163 .000 1.74 2.39 
 
6 2.067* .163 .000 1.74 2.39 
3 1 -6.033* .163 .000 -6.36 -5.71 
 
2 -1.233* .163 .000 -1.56 -.91 
 
4 .833* .163 .000 .51 1.16 
 
5 .833* .163 .000 .51 1.16 
 
6 .833* .163 .000 .51 1.16 
4 1 -6.867* .163 .000 -7.19 -6.54 
 
2 -2.067* .163 .000 -2.39 -1.74 
 
3 -.833* .163 .000 -1.16 -.51 
 
5 .000 .163 1.000 -.32 .32 
 
6 .000 .163 1.000 -.32 .32 
5 1 -6.867* .163 .000 -7.19 -6.54 
 
2 -2.067* .163 .000 -2.39 -1.74 
 
3 -.833* .163 .000 -1.16 -.51 
 
4 .000 .163 1.000 -.32 .32 
 
6 .000 .163 1.000 -.32 .32 
6 1 -6.867* .163 .000 -7.19 -6.54 
 
2 -2.067* .163 .000 -2.39 -1.74 
 
3 -.833* .163 .000 -1.16 -.51 
 
4 .000 .163 1.000 -.32 .32 
 5 .000 .163 1.000 -.32 .32 
 
*. The mean difference is significant at the 0.05 level. 
 
 PREPROCEDURE VAS Vs VAS 6( AT 2 MONTHS)- Paired T-test 
 
 Mean preprocedure VAS is 8.67 and that of VAS 6 is 1.80 with a 
negative correlation of -0.425 between these two statistically significant 
at 0.05 level. 
PAIRED SAMPLE STATISTICS 
PAIRED  
SAMPLES MEAN N 
STANDARD 
DEVIATION 
STD ERROR 
MEAN 
Pair 1 PP  VAS 8.67 30 .884 .161 
VAS 6 1.80 30 .551 .101 
 
PAIRED SAMPLES CORRELATIONS 
Paired  Samples N Correlation Sig. 
Pair 1 PP  VAS & VAS 6 30 -.425 .019
 
 
 Paired T-test between these two showed a mean difference of 6.867 ± 
0.448 with a standard deviation of 1.224 which is statistically significant 
at 0.000 level. 
 
 PAIRED T-TEST BETWEEN PP VAS 1 & VAS 6 
 Paired Differences    
Paired 
Samples 
 
95% Confidence 
Interval of the 
Difference 
   
  
Mean 
Std. 
Deviation 
Std. 
Error 
Mean Lower Upper T Df 
Sig. (2-
tailed) 
Pair 1 PP  
VAS1 - 
VAS 6 
6.867 1.224 .224 6.410 7.324 30.720 29 .000 
 
 
CORRELATION STATISTICS BETWEEN AGE Vs PAIN INTENSITY 
 Correlation analysis between age and different VAS scores was 
attempted. DIFFERENCE VAS in the analysis refers to the difference in 
the pain intensity score between PP VAS 1 and VAS 6.  
 Mean age was 42.97 with a standard deviation of 9.156 and the mean 
difference VAS was 6.87 with a standard deviation of 1.224. 
 The correlation analysis showed, positive correlation between age 
and VAS 2 (Pearson correlation of 0.508 significant at 0.0l level). A 
positive correlation also exists between age and VAS 3 (Pearson 
correlation of 0.370 significant at 0.05 level) and also with Difference 
VAS (Pearson correlation of 0.387 significant at 0.05 level).  
 DESCRIPTIVE STATISTICS 
 
 Mean Std. Deviation N 
AGE 42.97 9.156 30 
PP  VAS 1 8.67 .884 30 
VAS 2 3.87 .629 30 
VAS 3 2.63 .556 30 
VAS 4 1.80 .551 30 
VAS 5 1.80 .551 30 
VAS 6 1.80 .551 30 
DIFFERENCE VAS 6.87 1.224 30 
 
There is a positive correlation between PP VAS 1 with VAS 2 
(Pearson correlation of 0.476 significant at 0.0l level) and with 
Difference VAS (Pearson correlation of 0.913 significant at 0.0l level). 
There is a negative correlation between PP VAS 1 with VAS 4, 
VAS 5 and VAS 6(Pearson correlation of -0.425 significant at 0.05 level). 
There is a positive correlation between VAS 2 with VAS 3 
(Pearson correlation of 0.743 significant at 0.0l level). 
There is a positive correlation between VAS 5 and VAS 6 (Pearson 
correlation of 1.000 significant at 0.0l level). 
                       CORRELATIONS    
  
AGE 
PP 
VAS1 
VAS2 VAS3 VAS 4 VAS 4 VAS 5 
DIFF 
VAS 
AG
E 
Pearson 
Correlation 
1 .352 .508** .370* -.295 -.295 -.295 .387* 
Sig. (2-tailed)  .056 .004 .044 .113 .113 .113 .035 
N 30 30 30 30 30 30 30 30 
PP 
VA
S1 
Pearson 
Correlation 
.352 1 .476** .164 -.425* -.425* -.425* .913** 
Sig. (2-tailed) .056  .008 .387 .019 .019 .019 .000 
N 30 30 30 30 30 30 30 30 
VA
S2 
Pearson 
Correlation 
.508** .476** 1 .743** .020 .020 .020 .334 
Sig. (2-tailed) .004 .008  .000 .917 .917 .917 .071 
N 30 30 30 30 30 30 30 30 
VA
S3 
Pearson 
Correlation 
.370* .164 .743** 1 .203 .203 .203 .027 
Sig. (2-tailed) .044 .387 .000  .283 .283 .283 .887 
N 30 30 30 30 30 30 30 30 
VA
S 4 
Pearson 
Correlation 
-.295 -.425* .020 .203 1 1.000** 1.000** -.757** 
Sig. (2-tailed) .113 .019 .917 .283  .000 .000 .000 
N 30 30 30 30 30 30 30 30 
VA
S 5 
Pearson 
Correlation 
-.295 -.425* .020 .203 1.000** 1 1.000** -.757** 
Sig. (2-tailed) .113 .019 .917 .283 .000  .000 .000 
N 30 30 30 30 30 30 30 30 
VA
S 6 
Pearson 
Correlation 
-.295 -.425* .020 .203 1.000** 1.000** 1 -.757** 
Sig. (2-tailed) .113 .019 .917 .283 .000 .000  .000 
N 30 30 30 30 30 30 30 30 
DIF
FE
RE 
NC
E 
 
VA
S 
Pearson 
Correlation 
.387* .913** .334 .027 -.757** -.757** -.757** 1 
Sig. (2-tailed) .035 .000 .071 .887 .000 .000 .000  
N 30 30 30 30 30 30 30 30 
**. Correlation is significant at the 0.01 level (2-tailed).    
*. Correlation is significant at the 0.05 level (2-tailed).    
 There is a positive correlation between VAS 4 with VAS 5 and VAS 
6 (Pearson correlation of 1.000 significant at 0.0l level). 
There is a negative correlation between Difference VAS with VAS 
4, VAS 5 and VAS 6 (Pearson correlation of -0.757 significant at 0.0l 
level). 
 
GENDER Vs PAIN INTENSITY STATISTICS – 
 
In this study involving 30 patients, there were 17 males and 13 
females. 
The mean pain intensity of males are 8.65, 3.94, 2.71, 1.82, 1.82, 
1.82 and 6.82 for PP VAS 1, VAS 2, VAS 3, VAS 4, VAS 5, VAS 6 and 
Difference VAS respectively. 
The mean pain intensity of females are 8.69, 3.77, 2.54, 1.77, 1.77, 
1.77 and 6.92 for PP VAS 1, VAS 2, VAS 3, VAS 4, VAS 5, VAS 6 and 
Difference VAS respectively. 
 The standard deviation for males are 0.702, 0.659, 0.588, 0.529, 0.529, 
0.529 and 1.015 and that for females are 1.109, 0.599, 0.519, 0.599, 0.599, 
0.599 and 1.498 for PP VAS to VAS 6 and difference VAS respectively. 
 GROUP STATISTICS 
 
 
S
E
X N 
Mea
n 
Std. 
Deviation 
Std. Error 
Mean 
PP  
VAS 1 
1 17 8.65 .702 .170 
2 13 8.69 1.109 .308 
VAS2 1 17 3.94 .659 .160 
2 13 3.77 .599 .166 
VAS3 1 17 2.71 .588 .143 
2 13 2.54 .519 .144 
VAS 4 1 17 1.82 .529 .128 
2 13 1.77 .599 .166 
VAS 5 1 17 1.82 .529 .128 
2 13 1.77 .599 .166 
VAS 6 1 17 1.82 .529 .128 
2 13 1.77 .599 .166 
DIFFE
RENC
E VAS 
1 17 6.82 1.015 .246 
2 13 6.92 1.498 .415 
SEX 1 – MALE / SEX 2 – FEMALE 
 
GENDER Vs MEAN VAS CHART 
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 INDEPENDENT SAMPLES TEST 
   
 
  
  
  Levene's Test 
 for Equality 
 of Variances 
t-test for Equality of Means 
  
Sig. 
 (2-
tailed) 
Mean  
Differen
ce 
Std. 
Error 
Differen
ce 
95% Confidence 
Interval of the 
Difference 
  F Sig. Lower Upper 
PP  
VAS1 
Equal variances 
assumed 
5.012 .033 .892 -.045 .331 -.724 .634 
Equal variances 
not assumed   
.899 -.045 .352 -.781 .690 
VAS2 Equal variances 
assumed 
.038 .846 .468 .172 .234 -.306 .650 
Equal variances 
not assumed   
.462 .172 .231 -.301 .645 
VAS3 Equal variances 
assumed 
.000 .988 .423 .167 .206 -.255 .590 
Equal variances 
not assumed   
.416 .167 .203 -.248 .583 
VAS 4 Equal variances 
assumed 
.459 .504 .794 .054 .206 -.368 .477 
Equal variances 
not assumed   
.798 .054 .210 -.379 .487 
VAS 5 Equal variances 
assumed 
.459 .504 .794 .054 .206 -.368 .477 
Equal variances 
not assumed   
.798 .054 .210 -.379 .487 
VAS 6 Equal variances 
assumed 
.459 .504 .794 .054 .206 -.368 .477 
Equal variances 
not assumed   
.798 .054 .210 -.379 .487 
DIFFER
ENCE 
VAS 
Equal variances 
assumed 
5.424 .027 .830 -.100 .459 -1.039 .840 
Equal variances 
not assumed   
.839 -.100 .483 -1.107 .907 
NOT SIGNIFICANT 
Independent samples analysis between different VAS scores and 
gender, shows no statistical significance at 0.05 level indicating that 
gender does not play any significance in the VAS scores or in response to 
procedure. 
 DISEASE  TYPE  Vs  PAIN INTENSITY  STATISTICS - 
 
  Patients involved in this study belonged to four types of disease namely 
CHRONIC PANCREATITIS (TYPE I), PANCREATIC CARCINOMA 
(TYPE II), PERIAMPULLARY CARCINOMA (TYPE III) and GASTRIC 
CARCINOMA (TYPE IV). 
   
The mean, standard deviation, minimum and maximum PP VAS 1 
values for four diseases are 8.07 ± 0.306, 0.594, 7 and 9 for (Type I), 9.00 
±0.456, 0.577, 8 and 10 for (Type II), 10.00, 0, 10, and 10 for (Type III) 
and 9.00±0.816, 0.816, 8 and 10 for (Type IV). 
DISEASE TYPE Vs MEAN VAS SCORES 
 
0 2 4 6 8 10 12
CHRONIC PANCREATITIS
PANCREATIC CARCINOMA
PERIAMPULLARY CARCINOMA
GASTRIC CARCINOMA DIFF VAS
VAS 6
VAS 5
VAS 4
VAS 3
VAS 2
PP VAS 1
 DESCRIPTORS 
 
    
FACTORS 
 
95% Confidence 
 Interval for Mean 
  
  
N Mean 
Std. 
Deviation Std. Error 
Lower  
Bound 
Upper 
 Bound Minimum Maximum 
PP  
VAS1 
1 15 8.07 .594 .153 7.74 8.40 7 9 
2 7 9.00 .577 .218 8.47 9.53 8 10 
3 4 10.00 .000 .000 10.00 10.00 10 10 
4 4 9.00 .816 .408 7.70 10.30 8 10 
Total 30 8.67 .884 .161 8.34 9.00 7 10 
VAS2 1 15 3.60 .507 .131 3.32 3.88 3 4 
2 7 3.71 .488 .184 3.26 4.17 3 4 
3 4 4.75 .500 .250 3.95 5.55 4 5 
4 4 4.25 .500 .250 3.45 5.05 4 5 
Total 30 3.87 .629 .115 3.63 4.10 3 5 
VAS3 1 15 11 .516 .133 2.25 2.82 2 3 
2 7 2.43 .535 .202 1.93 2.92 2 3 
3 4 3.00 .000 .000 3.00 3.00 3 3 
4 4 3.00 .816 .408 1.70 4.30 2 4 
Total 30 2.63 .556 .102 2.43 2.84 2 4 
VAS 4 1 15 2.07 .258 .067 1.92 2.21 2 3 
2 7 1.14 .378 .143 .79 1.49 1 2 
3 4 1.75 .500 .250 .95 2.55 1 2 
4 4 2.00 .816 .408 .70 3.30 1 3 
Total 30 1.80 .551 .101 1.59 2.01 1 3 
VAS 5 1 15 2.07 .258 .067 1.92 2.21 2 3 
2 7 1.14 .378 .143 .79 1.49 1 2 
3 4 1.75 .500 .250 .95 2.55 1 2 
4 4 2.00 .816 .408 .70 3.30 1 3 
Total 30 1.80 .551 .101 1.59 2.01 1 3 
VAS 6 1 15 2.07 .258 .067 1.92 2.21 2 3 
2 7 1.14 .378 .143 .79 1.49 1 2 
3 4 1.75 .500 .250 .95 2.55 1 2 
4 4 2.00 .816 .408 .70 3.30 1 3 
Total 30 1.80 .551 .101 1.59 2.01 1 3 
DIFFE 
RENCE 
VAS 
1 15 6.00 .655 .169 5.64 6.36 5 7 
2 7 7.86 .690 .261 7.22 8.50 7 9 
3 4 8.25 .500 .250 7.45 9.05 8 9 
4 4 7.00 1.633 .816 4.40 9.60 5 9 
Total 30 6.87 1.224 .224 6.41 7.32 5 9 
 
  
 DISEASE Vs VAS SCORE 
DISEASE PPVAS   
1 
VAS 
2 
VAS 
3 
VAS 
4 
VAS 
5 
VAS 
6 
DIFF 
VAS 
 (1 – 6) % 0F 
REDUCTION 
I 8.07 3.60 2.61 2.07 2.07 2.07 6.00 74 
II 9.00 3.71 2.43 1.14 1.14 1.14 7.86 88 
III 10.00 4.75 3.00 1.75 1.75 1.75 8.25 82 
IV 9.00 4.25 3.00 2.00 2.00 2.00 7.00 78 
 
Mean Preprocedure VAS (PP VAS 1) in the four disease types are 8.07, 
9, 10 and 9 respectively. Mean VAS at 2 months follow up for the disease 
types are 2.07, 1.14, 1.75 and 2 respectively.  
 
DISEASE Vs MINIMUM VAS 
 
0 2 4 6 8 10 12
VAS 4
PANCREATIC CARCINOMA
PERIAMPULLARY CARCINOMA
GASTRIC CARCINOMA
DIFF VAS
VAS 6
VAS 5
VAS 4
VAS 3 
VAS 2
PP VAS 1
 DISEASE Vs MAXIMUM VAS 
 
 
% REDUCTION OF PAIN Vs DISEASE TYPES 
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VAS 5
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VAS 2
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 Mean Difference VAS for the disease groups are 6, 7.86, 8.25 and 7 
respectively. Percentage of reduction of pain intensity are 74, 88, 82 and 
78 % respectively.  
Thus the procedure is effective in all four disease groups. Among the four 
diseases, this procedure is less effective with least reduction percentage 
of 74 % for Chronic Pancreatitis, which is an inflammatory condition.  
For malignancies, it is more effective with maximum relief in 
pancreatic carcinoma with a pain reduction percentage of 88% 
 
ANOVA 
 
 As there is analysis of VAS score at different intervals, repeated measures 
of the same variable, with the different disease types, between subject 
analysis done using ANOVA. 
 ANOVA for between subjects for Different VAS score and disease types 
shows increased F value of  13.23 and 12.729 for PP VAS 1 and 
Difference VAS both significant at 0.000 level. 
 The F value for VAS 4, 5 and 6 is 8.130 significant at 0.001 level. For 
VAS 2, F value is 6.555 significant at 0.002 level. 
 VAS 3 does not show any significance. 
ANOVA 
 
  Sum of Squares df Mean Square F Sig. 
PP  VAS1 Between Groups 13.733 3 4.578 13.323 .000 
Within Groups 8.933 26 .344 
  
Total 22.667 29 
   
VAS2 Between Groups 4.938 3 1.646 6.555 .002 
Within Groups 6.529 26 .251 
  
Total 11.467 29 
   
VAS3 Between Groups 1.519 3 .506 1.768 .178 
Within Groups 7.448 26 .286 
  
Total 8.967 29 
   
VAS 4 Between Groups 4.260 3 1.420 8.130 .001 
Within Groups 4.540 26 .175 
  
Total 8.800 29 
   
VAS 5 Between Groups 4.260 3 1.420 8.130 .001 
Within Groups 4.540 26 .175 
  
Total 8.800 29 
   
VAS 6 Between Groups 4.260 3 1.420 8.130 .001 
Within Groups 4.540 26 .175 
  
Total 8.800 29 
   
DIFFERENCE 
VAS 
Between Groups 25.860 3 8.620 12.729 .000 
Within Groups 17.607 26 .677 
  
Total 43.467 29 
   
               
  For within subjects analysis, POST HOC tests with multiple comparisons 
done. 
 POST HOCS TEST 
MULTIPLE COMPARISONS 
 
Depen
dent 
Variabl
e 
(I) 
DISEA
SE 
CODE 
(J) 
DISEA
SE 
CODE 
 95% Confidence Interval 
Mean Difference 
(I-J) Std. Error Sig. Lower Bound Upper Bound 
PP  
VAS1 
1 2 -.933* .268 .002 -1.48 -.38 
3 -1.933* .330 .000 -2.61 -1.26 
4 -.933* .330 .009 -1.61 -.26 
2 1 .933* .268 .002 .38 1.48 
3 -1.000* .367 .011 -1.76 -.24 
4 .000 .367 1.000 -.76 .76 
3 1 1.933* .330 .000 1.26 2.61 
2 1.000* .367 .011 .24 1.76 
4 1.000* .414 .023 .15 1.85 
4 1 .933* .330 .009 .26 1.61 
2 .000 .367 1.000 -.76 .76 
3 -1.000* .414 .023 -1.85 -.15 
VAS2 1 2 -.114 .229 .622 -.59 .36 
3 -1.150* .282 .000 -1.73 -.57 
4 -.650* .282 .029 -1.23 -.07 
2 1 .114 .229 .622 -.36 .59 
3 -1.036* .314 .003 -1.68 -.39 
4 -.536 .314 .100 -1.18 .11 
3 1 1.150* .282 .000 .57 1.73 
2 1.036* .314 .003 .39 1.68 
4 .500 .354 .170 -.23 1.23 
4 1 .650* .282 .029 .07 1.23 
2 .536 .314 .100 -.11 1.18 
3 -.500 .354 .170 -1.23 .23 
VAS3 1 2 .105 .245 .672 -.40 .61 
3 -.467 .301 .133 -1.09 .15 
4 -.467 .301 .133 -1.09 .15 
2 1 -.105 .245 .672 -.61 .40 
3 -.571 .335 .100 -1.26 .12 
4 -.571 .335 .100 -1.26 .12 
3 1 .467 .301 .133 -.15 1.09 
2 .571 .335 .100 -.12 1.26 
4 .000 .378 1.000 -.78 .78 
4 1 .467 .301 .133 -.15 1.09 
2 .571 .335 .100 -.12 1.26 
3 .000 .378 1.000 -.78 .78 
VAS 4 1 2 .924* .191 .000 .53 1.32 
3 .317 .235 .190 -.17 .80 
4 .067 .235 .779 -.42 .55 
 2 1 -.924* .191 .000 -1.32 -.53 
3 -.607* .262 .029 -1.15 -.07 
4 -.857* .262 .003 -1.40 -.32 
3 1 -.317 .235 .190 -.80 .17 
2 .607* .262 .029 .07 1.15 
4 -.250 .295 .405 -.86 .36 
4 1 -.067 .235 .779 -.55 .42 
2 .857* .262 .003 .32 1.40 
3 .250 .295 .405 -.36 .86 
VAS 5 1 2 .924* .191 .000 .53 1.32 
3 .317 .235 .190 -.17 .80 
4 .067 .235 .779 -.42 .55 
2 1 -.924* .191 .000 -1.32 -.53 
3 -.607* .262 .029 -1.15 -.07 
4 -.857* .262 .003 -1.40 -.32 
3 1 -.317 .235 .190 -.80 .17 
2 .607* .262 .029 .07 1.15 
4 -.250 .295 .405 -.86 .36 
4 1 -.067 .235 .779 -.55 .42 
2 .857* .262 .003 .32 1.40 
3 .250 .295 .405 -.36 .86 
VAS 6 1 2 .924* .191 .000 .53 1.32 
3 .317 .235 .190 -.17 .80 
4 .067 .235 .779 -.42 .55 
2 1 -.924* .191 .000 -1.32 -.53 
3 -.607* .262 .029 -1.15 -.07 
4 -.857* .262 .003 -1.40 -.32 
3 1 -.317 .235 .190 -.80 .17 
2 .607* .262 .029 .07 1.15 
4 -.250 .295 .405 -.86 .36 
4 1 -.067 .235 .779 -.55 .42 
2 .857* .262 .003 .32 1.40 
3 .250 .295 .405 -.36 .86 
DIFFE
RENC
E VAS 
1 2 -1.857* .377 .000 -2.63 -1.08 
3 -2.250* .463 .000 -3.20 -1.30 
4 -1.000* .463 .040 -1.95 -.05 
2 1 1.857* .377 .000 1.08 2.63 
3 -.393 .516 .453 -1.45 .67 
4 .857 .516 .109 -.20 1.92 
3 1 2.250* .463 .000 1.30 3.20 
2 .393 .516 .453 -.67 1.45 
4 1.250* .582 .041 .05 2.45 
4 1 1.000* .463 .040 .05 1.95 
2 -.857 .516 .109 -1.92 .20 
3 -1.250* .582 .041 -2.45 -.05 
*. The mean difference is significant at the 0.05 level. 
 With PP VAS 1 as the dependent variable, the mean difference in 
within subject analysis, is significant at 0.05 level for all disease groups, 
except for 2 and 4. 
With VAS 2 as the dependent variable, the mean difference in within 
subject analysis, is significant at 0.05 level within 1 – 3, 1 – 4 and 2 – 3 
with no significance within 1-2, 2-4 and 3-4. 
  With VAS 3 as dependent variable, there is no statistically significant 
difference in the means within the disease groups. 
For VAS 4, VAS 5 and VAS 6 as dependent variable, mean difference is 
significant within 1-2, 2-3, 2-4 and so significance within 1-3, 1-4 and 3-
4. 
With Difference VAS as dependent variable, mean difference is 
statistically significant within 1-2, 1-3 and 1-4 with no significance 
within 2-3 and 2-4. 
 
REPEATED MEASURES ANOVA –  
  
Sphericity is an important assumption of repeated measures of ANOVA. It 
refers to difference in VARIANCES of differences between all possible 
pairs of groups. If there is no difference, sphericity is maintained.  
 Sphericity is given by Mauchly’s test (α). If α < 0.05, sphericity is lost, 
thereby rejecting the null hypothesis that variances are equal. When  
  
  
 
 
 
    
 
sphericity is violated, F ratio may be erroneously large. To prevent this, 
three types of corrections are denoted by – ε (epsilon). Farther the epsilon 
value from 1, farther is the violation.  
In this study, sphericity is violated (α – 0.000) and the degree of 
violation is large given by Greenhouse – Geisser epsilon (ε) – 0.325. 
TESTS OF WITHIN-SUBJECTS EFFECTS 
Source 
 
Type III Sum of 
Squares df Mean Square F Sig. 
factor1 Sphericity Assumed 1086.561 5 217.312 666.571 .000
Greenhouse-Geisser 1086.561 1.623 669.678 666.571 .000
Huynh-Feldt 1086.561 1.705 637.323 666.571 .000
Lower-bound 1086.561 1.000 1086.561 666.571 .000
Error(factor1) Sphericity Assumed 47.272 145 .326 
  
Greenhouse-Geisser 47.272 47.053 1.005 
  
Huynh-Feldt 47.272 49.442 .956 
  
Lower-bound 47.272 29.000 1.630 
  
 
 Repeated  measures ANOVA gives a GREENHOUSE-GEISSER 
F value of  669.571 which is significant at 0.000 level. 
Within 
Subjec
ts 
Effect 
 
a
 
Mauchly's 
W 
Approx. Chi-
Square df Sig. 
factor1 .000 . 14 . 
Within 
Subjec
ts 
Effect 
Epsilona 
Greenhouse-
Geisser 
Huynh-
Feldt 
Lower-
bound 
factor1 .325 .341 .200 
 F ratio can also be calculated using MANOVA – multivariate 
analysis. Wilk’s Lambda F value is 376.313 which is statistically 
significant at 0.000 level.  
MULTIVARIATE TESTS 
Effect Value F Hypothesis df Error df Sig. 
factor1 Pillai's Trace .977 376.313a 3.000 27.000 .000 
Wilks' Lambda .023 376.313a 3.000 27.000 .000 
Hotelling's Trace 41.813 376.313a 3.000 27.000 .000 
Roy's Largest Root 41.813 376.313a 3.000 27.000 .000 
 
TESTS OF WITHIN-SUBJECTS CONTRASTS 
Source factor1 
Type III Sum of 
Squares Df Mean Square F Sig. 
factor1 Linear 566.800 1 566.800 1054.666 .000
Quadratic 474.067 1 474.067 620.419 .000
Cubic 41.082 1 41.082 196.325 .000
Order 4 2.411 1 2.411 41.211 .000
Order 5 2.201 1 2.201 36.206 .000
Error(factor1) Linear 15.585 29 .537 
  
Quadratic 22.159 29 .764 
  
Cubic 6.068 29 .209 
  
Order 4 1.696 29 .058 
  
Order 5 1.763 29 .061 
  
 
 
 
 
 Thus there is statistically significant reduction in pain intensity 
within the groups indicating success of the procedure. 
 ANALYSIS OF COMPLICATIONS –  
 Three complications namely Hypotension, Back pain and shoulder pain 
were observed. Let us analyse if these were dependent on GENDER or 
DISEASE type. 
GENDER  Vs  HYPOTENSION 
 
CROSS TAB 
   HYPOTENSION  
   ABSENT PRESENT Total 
SEX F Count 4 9 13 
% within HYPOTENSION 33.3% 50.0% 43.3% 
% of Total 13.3% 30.0% 43.3% 
M Count 8 9 17 
% within HYPOTENSION 66.7% 50.0% 56.7% 
% of Total 26.7% 30.0% 56.7% 
 
Total Count 12 18 30 
% within HYPOTENSION 100.0% 100.0% 100.0% 
% of Total 40.0% 60.0% 100.0% 
 
 
 
 
0
1
2
3
4
5
6
7
8
9
10
FEMALES MALES
N
O
 O
F
 P
A
T
IE
N
T
S
 W
IT
H
 
H
Y
P
O
T
E
N
S
IO
N
A
S
 C
O
M
P
L
IC
A
T
IO
N
GENDER
ABSENT 
PRESENT
 CHI SQUARE TEST 
 
Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square .814a 1 .367   
Continuity Correctionb .277 1 .599   
Likelihood Ratio .824 1 .364   
Fisher's Exact Test    .465 .301
N of Valid Cases 30     
 
 9 out of 13 females and 9 out of 17 males had hypotension. Pearson Chi 
Square value is 0.367, hence statistically insignificant i.e they are 
independent.     
GENDER  Vs  BACK PAIN 
CROSS TAB   
   BACK PAIN  
   ABSENT PRESENT Total 
SEX F Count 5 8 13 
% within BACK PAIN 31.3% 57.1% 43.3% 
% of Total 16.7% 26.7% 43.3% 
M Count 11 6 17 
% within BACK PAIN 68.8% 42.9% 56.7% 
% of Total 36.7% 20.0% 56.7% 
 Total Count 16 14 30 
% within BACK PAIN 100.0% 100.0% 100.0% 
% of Total 53.3% 46.7% 100.0% 
 
  8 0ut of 13 females and 6 0ut of 17 males had back pain with a p 
value of 0.153 with no statistical significance. Hence back pain is 
independent of gender.   
  
 
CHI-SQUARE TESTS 
 
Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 2.039
a
 1 .153   
Continuity Correctionb 1.121 1 .290   
Likelihood Ratio 2.058 1 .151   
Fisher's Exact Test  
  
.269 .145 
N of Valid Cases 30     
 
 
 
GENDER VS SHOULDER PAIN 
 
 6 out of 13 females and 6 out of 17 males had shoulder post procedure. 
Pearson Chi square value is 0.547. Hence statistically insignificant i.e 
gender and shoulder pain are independent. 
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 CROSS TAB 
   SHOULDER PAIN  
   ABSENT PRESENT Total 
SEX F Count 7 6 13 
% within SHOULDER PAIN 38.9% 50.0% 43.3% 
% of Total 23.3% 20.0% 43.3% 
M Count 11 6 17 
% within SHOULDER PAIN 61.1% 50.0% 56.7% 
% of Total 36.7% 20.0% 56.7% 
 
Total Count 18 12 30 
% within SHOULDER PAIN 100.0% 100.0% 100.0% 
% of Total 60.0% 40.0% 100.0% 
 
 
 
CHI SQUARE TESTS 
 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square .362a 1 .547   
Continuity Correctionb .051 1 .821   
Likelihood Ratio .361 1 .548   
Fisher's Exact Test    .711 .410 
N of Valid Cases 30     
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GENDER
ABSENT
PRESENT
 HYPOTENSION Vs AGE & DIFFERENCE VAS 
GROUP STATISTICS 
 
 
HYPOTENSION N Mean Std. Deviation 
Std. Error 
Mean 
AGE PRESENT 18 48.83 6.706 1.581 
ABSENT 12 34.17 3.271 .944 
VAS DIFFERENCE PRESENT 18 7.06 1.434 .338 
ABSENT 12 6.58 .793 .229 
 
INDEPENDENT SAMPLES TEST 
 
  
Levene's Test 
for  
Equality of 
 Variances t-test for Equality of Means 
  
  
F Sig. T Df 
Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference Lower Upper 
AGE Equal 
variances 
assumed 
13.338 .001 7.011 28 .000 14.667 2.092 10.382 18.952 
Equal 
variances not 
assumed 
  
7.966 26.150 .000 14.667 1.841 10.883 18.450 
VAS 
DIFFE
RENC
E 
Equal 
variances 
assumed 
10.701 .003 1.036 28 .309 .472 .456 -.461 1.406 
Equal 
variances not 
assumed 
  
1.157 27.298 .257 .472 .408 -.365 1.309 
 
  
Let us now analyse the complications Vs age and Difference VAS scores. 
 P value for age Vs hypotension is 0.000, which is statistically 
significant indicating that age and hypotension are dependent variables. 
 P value for Difference VAS score Vs Hypotension is insignificant. 
 BACK PAIN Vs AGE & DIFFERENCE VAS 
 
GROUP STATISTICS 
 
 
BACK PAIN N Mean Std. Deviation 
Std. Error 
Mean 
AGE PRESENT 14 50.93 6.044 1.615 
ABSENT 16 36.00 4.412 1.103 
 
 
PRESENT 14 7.29 1.437 .384 
ABSENT 16 6.50 .894 .224 
 
INDEPENDENT SAMPLES TEST 
 
  
Levene's Test 
for  
Equality of 
 Variances t-test for Equality of Means 
  
  
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference Lower Upper 
AGE Equal 
variances 
assumed 
2.845 .103 7.794 28 .000 14.929 1.915 11.005 18.852 
Equal 
variances not 
assumed 
  
7.632 23.518 .000 14.929 1.956 10.887 18.970 
VAS 
DIFF
ERE
NCE 
Equal 
variances 
assumed 
6.275 .018 1.823 28 .079 .786 .431 -.097 1.669 
Equal 
variances not 
assumed 
  
1.768 21.193 .092 .786 .444 -.138 1.710 
 
P value for age Vs back pain is 0.000, which is statistically 
significant indicating that age and Back pain are dependent variables. 
 P value for Difference VAS score Vs Back pain is insignificant. 
 SHOULDER PAIN Vs AGE & DIFFERENCE VAS 
GROUP STATISTICS 
 
 SHOULDER 
PAIN N Mean Std. Deviation 
Std. Error 
Mean 
AGE PRESENT 12 52.50 4.890 1.412 
ABSENT 18 36.61 4.539 1.070 
VAS DIFFERENCE PRESENT 12 7.25 1.422 .411 
ABSENT 18 6.61 1.037 .244 
 
INDEPENDENT SAMPLES TEST 
 
  
Levene's Test 
for  
Equality of 
 Variances t-test for Equality of Means 
  
  
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference Lower Upper 
AGE Equal 
variances 
assumed 
.060 .808 9.110 28 .000 15.889 1.744 12.316 19.462 
Equal 
variances 
not 
assumed 
  
8.971 22.471 .000 15.889 1.771 12.220 19.558 
VAS 
DIFF
ERE
NCE 
Equal 
variances 
assumed 
2.698 .112 1.425 28 .165 .639 .448 -.280 1.557 
Equal 
variances 
not 
assumed 
  
1.337 18.661 .197 .639 .478 -.362 1.640 
 
P value for age Vs shoulder pain is 0.000, which is statistically 
significant indicating that age and shoulder pain are dependent 
variables. 
 P value for Difference VAS score Vs shoulder pain is insignificant. 
 ANALYSIS OF COMPLICATIONS Vs DISEASE TYPE 
 
HYPOTENSION Vs DISEASE TYPE 
   HYPOTENSION  
   ABSENT PRESENT Total 
DISEASE 1 Count 8 7 15 
% within HYPOTENSION 66.7% 38.9% 50.0% 
% of Total 26.7% 23.3% 50.0% 
2 Count 2 5 7 
% within HYPOTENSION 16.7% 27.8% 23.3% 
% of Total 6.7% 16.7% 23.3% 
3 Count 1 3 4 
% within HYPOTENSION 8.3% 16.7% 13.3% 
% of Total 3.3% 10.0% 13.3% 
4 Count 1 3 4 
% within HYPOTENSION 8.3% 16.7% 13.3% 
% of Total 3.3% 10.0% 13.3% 
 Total Count 12 18 30 
% within HYPOTENSION 100.0% 100.0% 100.0% 
% of Total 40.0% 60.0% 100.0% 
 
 
0
1
2
3
4
5
6
7
8
9
DISEASE I DISEASE II DISEASE III DISEASE IV
N
O
  
O
F
 P
A
T
IE
N
T
S
 W
IT
H
H
Y
P
O
T
E
N
S
IO
N
ABSENT
PRESENT
 CHI-SQUARE TESTS 
 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 2.242a 3 .524 
Likelihood Ratio 2.280 3 .516 
Linear-by-Linear Association 1.676 1 .195 
N of Valid Cases 30   
 
 Disease type Vs hypotension analysis gives a Pearson Chi Square value 
of 0.524 which is statistically insignificant meaning both are 
independent. 
BACK PAIN  Vs DISEASE TYPE 
 
 
  
BACK PAIN  
   ABSENT PRESENT Total 
DISEASE 1 Count 11 4 15 
% within BACK PAIN 68.8% 28.6% 50.0% 
% of Total 36.7% 13.3% 50.0% 
2 Count 2 5 7 
% within BACK PAIN 12.5% 35.7% 23.3% 
% of Total 6.7% 16.7% 23.3% 
3 Count 2 2 4 
% within BACK PAIN 12.5% 14.3% 13.3% 
% of Total 6.7% 6.7% 13.3% 
4 Count 1 3 4 
% within BACK PAIN 6.3% 21.4% 13.3% 
% of Total 3.3% 10.0% 13.3% 
 Total Count 16 14 30 
% within BACK PAIN 100.0% 100.0% 100.0% 
% of Total 53.3% 46.7% 100.0% 
  
CHI SQUARE TESTS 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 5.443a 3 .142 
Likelihood Ratio 5.638 3 .131 
Linear-by-Linear Association 3.264 1 .071 
N of Valid Cases 30   
 
 
 Disease type Vs back pain analysis gives a Pearson Chi Square value of 
0.142 which is statistically insignificant meaning both are independent. 
SHOULDER PAIN Vs DISEASE TYPE 
 
   SHOULDER PAIN  
   ABSENT PRESENT Total 
DISEASE 1 Count 12 3 15 
% within SHOULDER PAIN 66.7% 25.0% 50.0% 
% of Total 40.0% 10.0% 50.0% 
2 Count 2 5 7 
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 % within SHOULDER PAIN 11.1% 41.7% 23.3% 
% of Total 6.7% 16.7% 23.3% 
3 Count 2 2 4 
% within SHOULDER PAIN 11.1% 16.7% 13.3% 
% of Total 6.7% 6.7% 13.3% 
4 Count 2 2 4 
% within SHOULDER PAIN 11.1% 16.7% 13.3% 
% of Total 6.7% 6.7% 13.3% 
 Total Count 18 12 30 
% within SHOULDER PAIN 100.0% 100.0% 100.0% 
% of Total 60.0% 40.0% 100.0% 
 
 
CHI SQUARE TESTS 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 5.714a 3 .126 
Likelihood Ratio 5.902 3 .116 
Linear-by-Linear Association 2.048 1 .152 
N of Valid Cases 30   
 
Disease type Vs shoulder pain analysis gives a Pearson value of 
0.126 which is statistically insignificant meaning both are independent. 
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CONCLUSION 
 
 
 
 
 CONCLUSION 
1) Mean percentage reduction of pain intensity between preprocedure 
VAS score and Immediate post procedure VAS score, immediate post 
procedure and 24 hours score, 24 hours and 1 week score and 
preprocedure and 2 months score are 55%, 32%, 31% and 80% 
respectively, all of which were statistically significant. 
2) The pain intensity score remained static from 1 week to 2 months post 
procedure. 
3) A negative correlation with statistical significance was observed 
between preprocedure score and 2 months score. 
4) A positive correlation with statistical significance was seen for Age 
with  Immediate postprocedure, 1 day and Difference VAS score. 
5) A positive correlation with statistical significance was seen between 
preprocedure and Immediate post procedure, Immediate post 
procedure and 24 hours, 1 week with 1 and 2 months, 1 month and 2 
months, preprocedure and difference VAS scores. 
6) A negative correlation with statistical significance is seen for 
preprocedure with 1 week score, Difference score with 1 week, 1 month 
and 2 months. 
 7) Gender does not have any statistical significance in the VAS scores or 
in the response to procedure. 
8) For preprocedure VAS score, the mean difference in within subject 
analysis is statistically significant for preprocedure VAS and immediate 
post procedure score. 
9) For Immediate post procedure score, the mean difference in within 
subject analysis is statistically significant for preprocedure with 24 
hours and 1 week and for immediate postprocedure score with 24 hours 
score. 
10) For 24 hours score, , the mean difference in within subject analysis 
is not statistically significant for any of the scores. 
11) For Difference VAS score, the mean difference in within subject 
analysis is statistically significant for preprocedure with immediate 
post procedure, 24 hours and 1 week. 
12) For Difference VAS score, the mean difference in within subject 
analysis is not statistically significant for immediate post procedure 
with 24 hours and 1 week. 
13) There is difference in the Variances of differences between all 
possible pairs of groups with statistical significance indicating, there is 
a true reduction in pain intensity post procedure. 
14) Procedure was more effective for malignancies than inflammatory 
condition. 
 15) Maximum percentage reduction in pain, of 88% was seen with 
pancreatic carcinoma. 
16) Least percentage reduction in pain, of 74% was seen with Chronic 
pancreatitis. 
17)  Hypotension was the commonest complication seen in 18 patients 
(9 males and 9 females). All these patients settled with intravenous 
fluids.  
18) Back pain was the second most common complication, seen in 14 
patients (6 males and 8 females).  
19) Shoulder pain was seen in 12 patients (6 males and 6 females). 
20) Absence of pain relief was not reported in this study. 
21) Complications were independent of Gender and Difference VAS 
score. 
22) Complications were dependent on Age with statistical significance. 
LIMITATIONS –  
1) Sample size is only 30. 
2) Number of patients in each disease type are not equal and also too 
small in the third and fourth type and hence the results cannot be 
generalised. 
3) Follow up is done only up to 2 months. Hence the long term benefits 
or worsening of pain beyond 2 months is not known. 
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BARNARD INSTITUTE OF RADIOLOGY 
INTERVENTIONAL RADIOLOGY DIVISION 
CT guided neurolytic procedures 
Name:      Age:   Sex: 
Address:      Mobile: 
I.P.No:      Ward: 
Department: 
Indication: 
Diagnosis: 
History of present illness: 
Past history: 
Treatment history: 
Details of Analgesic medication: 
Drug Dosage Duration 
   
 
Evaluation of pain Pre procedure: 
Site:       Intensity: 
Visual Analog Scale (VAS) 
 No pain 0 ………………………….. 10 Worst possible pain 
Graceleys Verbal Descriptor Scale: 
0 ……………………………………………………10 
Procedural/Post procedural complication: 
Follow up: 
Time  
Interval 
VAS GVDS Category scale Analgesic 
Dose 
Remarks 
IMMEDIATE 
     
24 HOURS 
     
1 WEEK 
     
1 MONTH 
     
2 MONTHS 
     
6 MONTHS 
     
 
Repeat of procedure (if any): 
 
Date:          Signature 
Place: 
  
MASTER CHART 
CT GUIDED CELIAC PLEXUS 
NEUROLYSIS 
S.N
O 
AG
E 
SE
X 
DIS 
EAS
E 
VISUAL ANALOG SCALE COMPLICATIONS 
PP  
VAS
1 
VAS 
2 
VA
S 3 
VA
S 4 
VA
S 5 
VA
S 6 
1 
- 
6 
HYP 
OTE 
NSION 
BACK  
PAIN 
SHOULDE
R PAIN 
1 28 M I 9 4 3 2 2 2 7       
2 34 F I 8 3 2 2 2 2 6       
3 39 M III 10 5 3 2 2 2 8 Present     
4 42 M I 8 4 3 2 2 2 6 Present     
5 58 F III 10 5 3 2 2 2 8 Present Present Present 
6 32 M I 8 3 2 2 2 2 6       
7 59 M III 10 5 3 1 1 1 9 Present Present Present 
8 41 F I 7 4 3 2 2 2 5 Present     
9 34 M I 8 3 2 2 2 2 6       
10 33 F I 7 3 2 2 2 2 5       
11 44 M I 8 4 2 2 2 2 6 Present     
12 47 F II 9 4 3 1 1 1 8 Present Present Present 
13 31 M I 9 3 2 2 2 2 7       
14 38 F II 9 4 2 2 2 2 7       
15 48 M I 8 4 3 3 3 3 5 Present Present Present 
16 52 F IV 8 4 3 3 3 3 5 Present Present Present 
17 33 M I 9 4 3 2 2 2 7       
18 40 F IV 10 4 2 1 1 1 9 Present Present   
19 57 M IV 9 5 4 2 2 2 7 Present Present Present 
20 43 F I 8 3 2 2 2 2 6 Present Present   
21 37 M II 8 3 2 1 1 1 7       
22 39 F III 10 4 3 2 2 2 8       
23 55 M II 9 4 3 1 1 1 8 Present Present Present 
24 45 F I 8 4 3 2 2 2 6 Present Present Present 
25 33 M I 8 4 3 2 2 2 6       
26 56 F II 10 3 2 1 1 1 9 Present Present Present 
27 53 M II 9 4 2 1 1 1 8 Present Present Present 
28 54 F II 9 4 3 1 1 1 8 Present Present Present 
29 46 M I 8 4 3 2 2 2 6 Present Present Present 
30 38 M IV 9 4 3 2 2 2 7       
 
 
 
  
 
WORK SHEET 
AGE GROUP 
YEARS MALE FEMALE TOTAL 
< 20 0 0 0 
20 – 40 9 5 14 
40 – 60 8 8 16 
> 60 0 0 0 
   
COMPLICATIONS 
CONDITION 
DISEASE I DISEASE II DISEASE III DISEASE IV TOTAL 
M F M F M F M F   
HYPOTENSION 4 3 2 3 2 1 1 2 18 
BACK PAIN 2 2 2 3 1 1 1 2 14 
SHOULDER PAIN 2 1 2 3 1 1 1 1 12 
TOTAL 8 6 6 9 4 3 3 5 44 
 
 
DISEASE CODING 
DISEASE CODE TOTAL MALE FEMALE 
CHRONIC PANCREATITIS I 15 10 5 
PANCREATIC CARCINOMA II 7 3 4 
PERIAMPULLARY CARCINOMA III 4 2 2 
GASTRIC CARCINOMA IV 4 2 2 
 
 
 
  
 
 
  
 
 
  
 
 
 
 
